1
|
Yamamoto M, Tamura M, Miyazaki R, Okada H, Wada N, Toi M, Murakami I. Mean computed tomography value to predict spread through air spaces in clinical N0 lung adenocarcinoma. J Cardiothorac Surg 2024; 19:260. [PMID: 38654352 PMCID: PMC11036729 DOI: 10.1186/s13019-024-02612-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2023] [Accepted: 03/05/2024] [Indexed: 04/25/2024] Open
Abstract
BACKGROUND The aim of this study was to assess the ability of radiologic factors such as mean computed tomography (mCT) value, consolidation/tumor ratio (C/T ratio), solid tumor size, and the maximum standardized uptake (SUVmax) value by F-18 fluorodeoxyglucose positron emission tomography to predict the presence of spread through air spaces (STAS) of lung adenocarcinoma. METHODS A retrospective study was conducted on 118 patients those diagnosed with clinically without lymph node metastasis and having a pathological diagnosis of adenocarcinoma after undergoing surgery. Receiver operating characteristics (ROC) analysis was used to assess the ability to use mCT value, C/T ratio, tumor size, and SUVmax value to predict STAS. Univariate and multiple logistic regression analyses were performed to determine the independent variables for the prediction of STAS. RESULTS Forty-one lesions (34.7%) were positive for STAS and 77 lesions were negative for STAS. The STAS positive group was strongly associated with a high mCT value, high C/T ratio, large solid tumor size, large tumor size and high SUVmax value. The mCT values were - 324.9 ± 19.3 HU for STAS negative group and - 173.0 ± 26.3 HU for STAS positive group (p < 0.0001). The ROC area under the curve of the mCT value was the highest (0.738), followed by SUVmax value (0.720), C/T ratio (0.665), solid tumor size (0.649). Multiple logistic regression analyses using the preoperatively determined variables revealed that mCT value (p = 0.015) was independent predictive factors of predicting STAS. The maximum sensitivity and specificity were obtained at a cutoff value of - 251.8 HU. CONCLUSIONS The evaluation of mCT value has a possibility to predict STAS and may potentially contribute to the selection of suitable treatment strategies.
Collapse
Affiliation(s)
- Marino Yamamoto
- Department of Thoracic Surgery, Kochi Medical School, Kohasu, Oko-Cho, Nankoku, Kochi, 783-8505, Japan
| | - Masaya Tamura
- Department of Thoracic Surgery, Kochi Medical School, Kohasu, Oko-Cho, Nankoku, Kochi, 783-8505, Japan.
| | - Ryohei Miyazaki
- Department of Thoracic Surgery, Kochi Medical School, Kohasu, Oko-Cho, Nankoku, Kochi, 783-8505, Japan
| | - Hironobu Okada
- Department of Thoracic Surgery, Kochi Medical School, Kohasu, Oko-Cho, Nankoku, Kochi, 783-8505, Japan
| | - Noriko Wada
- Department of Pathology, Kochi Medical School, Nankoku, Kochi, Japan
| | - Makoto Toi
- Department of Pathology, Kochi Medical School, Nankoku, Kochi, Japan
| | - Ichiro Murakami
- Department of Pathology, Kochi Medical School, Nankoku, Kochi, Japan
| |
Collapse
|
2
|
Hayashi Y, Yamamoto Y, Murakami I. Micromorphological observation of HLE cells under knockdown of Fascin using LV-SEM. Med Mol Morphol 2023; 56:257-265. [PMID: 37526656 DOI: 10.1007/s00795-023-00362-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Accepted: 06/19/2023] [Indexed: 08/02/2023]
Abstract
Liver cancer is one of the most prevalent cancers in Japan with hepatocellular carcinoma (HCC) as the major histological subtype. Successful novel treatments for HCC have been reported; however, recurrences or metastasis may occur, which results in poor prognoses and high mortality of HCC patients. Fascin, an actin-bundling protein, regulates cell adhesion, migration, and invasion. Its overexpression positively correlates with poor prognosis of malignant tumors, and Fascin is considered as one of the tumor biomarkers and therapeutic target proteins. In this study, we attempted to reveal the relationship between Fascin and HCC using HLE, one of the human HCC cell lines. We performed the study with classical immunocytochemistry and recently developed techniques, such as wound-healing assay, spheroid cultivation, and low-vacuum scanning electron microscopy (LV-SEM). Non-Fascin-knockdown (FKD) cell spheroid had a regular spherical appearance with tight cell-cell connections, while FKD cell spheroid had an irregular shape with loose cell-cell connections. Cells of non-FKD spheroid presented fibrous protrusions on the cell surface, contrarily, cells of FKD spheroids showed bulbous-shaped protrusions. Morphological observation of FKD and non-FKD HLE spheroids were performed using LV-SEM. Our study may help to reveal the roles of Fascin in the process of HCC formation and its malignancy.
Collapse
Affiliation(s)
- Yoshihiro Hayashi
- Department of Pathology, School of Medicine, Kochi University, 185-1, Kohasu, Oko-Cho, Nankoku, 783-8505, Japan
- Equipment of Support Planning Office, Kochi University, 185-1, Kohasu, Oko-Cho, Nankoku, 783-8505, Japan
| | - Yumiko Yamamoto
- Department of Diagnostic Pathology, Kochi University Hospital, Kochi University, 185-1, Kohasu, Oko-Cho, Nankoku, 783-8505, Japan.
| | - Ichiro Murakami
- Department of Pathology, School of Medicine, Kochi University, 185-1, Kohasu, Oko-Cho, Nankoku, 783-8505, Japan
- Department of Diagnostic Pathology, Kochi University Hospital, Kochi University, 185-1, Kohasu, Oko-Cho, Nankoku, 783-8505, Japan
| |
Collapse
|
3
|
Kitamura N, Hashida Y, Higuchi T, Ohno S, Sento S, Sasabe E, Murakami I, Yamamoto T, Daibata M. Detection of Merkel cell polyomavirus in multiple primary oral squamous cell carcinomas. Odontology 2023; 111:971-981. [PMID: 36964865 PMCID: PMC10492774 DOI: 10.1007/s10266-023-00807-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2022] [Accepted: 03/14/2023] [Indexed: 03/26/2023]
Abstract
Oral microbiome studies have mainly focussed on bacteria, with the relationship between viruses and oral cancers remaining poorly understood. Oral cancers can develop even in the absence of any history of daily smoking or drinking. Oral cancer patients frequently have multiple primary cancers in the oral cavity and other organs, such as the upper gastrointestinal tract. Merkel cell polyomavirus (MCPyV) is a novel oncovirus identified from a subtype of skin cancer in 2008. In this study, we investigated the potential involvement of MCPyV in the pathogenesis of oral squamous cell carcinoma (OSCC). Participants comprised 115 Japanese patients with OSCC (single primary: 109 tumours in 109 patients; multiple primaries: 16 tumours in 6 patients) treated in our department between 2014 and 2017. DNA was extracted from formalin-fixed paraffin-embedded specimens of primary lesions. MCPyV DNA copy counts were analysed by quantitative real-time polymerase chain reaction. Twenty-four of the 115 patients (20.9%) were positive for MCPyV DNA. No association was found between presence or absence of MCPyV DNA and clinical characteristics other than number of primary lesions. The MCPyV DNA-positive rate was significantly higher for multiple primary OSCCs (62.5%, 10/16 tumours) than for single primary OSCCs (16.5%, 18/109 tumours; P < 0.001). Furthermore, MCPyV DNA load was significantly higher for patients with multiple primaries (P < 0.05). MCPyV was observed more frequently and DNA load was significantly higher with multiple primary OSCCs than with single primary OSCC. MCPyV may play some role as an oncovirus for multiple primary OSCCs.
Collapse
Affiliation(s)
- Naoya Kitamura
- Department of Oral and Maxillofacial Surgery, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505 Japan
| | - Yumiko Hashida
- Department of Microbiology and Infection, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505 Japan
| | - Tomonori Higuchi
- Department of Microbiology and Infection, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505 Japan
| | - Seiji Ohno
- Department of Oral and Maxillofacial Surgery, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505 Japan
| | - Shinya Sento
- Department of Oral and Maxillofacial Surgery, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505 Japan
| | - Eri Sasabe
- Department of Oral and Maxillofacial Surgery, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505 Japan
| | - Ichiro Murakami
- Department of Pathology, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505 Japan
| | - Tetsuya Yamamoto
- Department of Oral and Maxillofacial Surgery, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505 Japan
| | - Masanori Daibata
- Department of Microbiology and Infection, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505 Japan
| |
Collapse
|
4
|
Yamamoto Y, Hayashi Y, Sakaki H, Murakami I. Downregulation of fascin induces collective cell migration in triple‑negative breast cancer. Oncol Rep 2023; 50:150. [PMID: 37326137 DOI: 10.3892/or.2023.8587] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2022] [Accepted: 04/20/2023] [Indexed: 06/17/2023] Open
Abstract
Breast cancer (BC) is one of the most common types of cancer affecting female patients. Triple‑negative BC (TNBC) is an aggressive subtype. Fascin, an actin‑bundling protein, serves a significant role in cancer metastasis. Fascin overexpression is associated with poor prognosis of BC. To confirm the relationship between fascin expression and BC malignancy, the present study reviewed clinical data from 100 Japanese patients with BC and performed fresh immunohistochemical fascin examination of tissue samples. Statistical analyses showed metastasis or recurrence in 11 of 100 patients and a significant association between high fascin expression and poor prognosis. The TNBC subtype was also associated with high fascin expression. However, a few cases developed poor prognosis regardless of negative or slightly positive fascin expression. The present study established fascin knockdown (FKD) MDA‑MB‑231, a TNBC cell line, and investigated morphological effects of fascin on TNBC cells. FKD cells exhibited cell‑cell connections and bulbous nodules of various sizes on the cell surface. Conversely, non‑FKD MDA‑MB‑231 cells exhibited loose cell‑cell connections with numerous filopodia on the cell surface. Filopodia, actin‑rich plasma membrane protrusions, are composed of fascin and control cell‑cell interaction, migration and wound healing. Cancer metastasis is conventionally classified into two mechanisms: single and collective cell migration. Fascin increases cancer metastasis by single cell migration via filopodia on the cell surface. However, the present study suggested that following FKD, TNBC cells lost filopodia and exhibited collective cell migration.
Collapse
Affiliation(s)
- Yumiko Yamamoto
- Department of Diagnostic Pathology, Kochi University Hospital, Kochi University, Kohasu, Nankoku, Kochi 783‑8505, Japan
| | - Yoshihiro Hayashi
- Equipment of Support Planning Office, Kochi University, Kohasu, Nankoku, Kochi 783‑8505, Japan
| | - Hideyuki Sakaki
- Department of Nutritional Sciences for Wellbeing, Kansai University of Welfare Sciences, Kashiwara, Osaka 582‑0026, Japan
| | - Ichiro Murakami
- Department of Diagnostic Pathology, Kochi University Hospital, Kochi University, Kohasu, Nankoku, Kochi 783‑8505, Japan
| |
Collapse
|
5
|
Yorita K, Fujii T, Nagao T, Murakami I, Hashida Y, Higuchi T, Daibata M, Toi M, Ayada Y, Igawa T. Kimura disease forming a human polyomavirus 6–negative parotid gland nodule with prominent squamous metaplasia in a young female: A case report. Radiol Case Rep 2023; 18:1933-1938. [PMID: 36970233 PMCID: PMC10030818 DOI: 10.1016/j.radcr.2023.02.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2023] [Revised: 02/10/2023] [Accepted: 02/12/2023] [Indexed: 03/18/2023] Open
Abstract
A case of an asymptomatic 19-year-old woman with Kimura disease presenting with a nodule in the right parotid gland is presented. She had a medical history of atopic dermatitis and noticed a mass on her right-side neck. Cervical lymphadenopathy was clinically diagnosed. The initial management plan was to observe the lesion, which had enlarged from 1 cm to 2 cm in diameter 6 months later. An excisional biopsy was performed, and the pathology confirmed an eosinophil-containing inflammatory parotid gland lesion with many squamous nests and cysts, mimicking a parotid gland tumor. High serum immunoglobulin E levels, peripheral blood eosinophilia, and pathological and genetic diagnoses confirmed Kimura disease. The lesion tested negative for human polyomavirus 6. No recurrence was observed 15 months after the biopsy. The prognosis of Kimura disease without human polyomavirus 6 infection may be favorable; however, further validation of this hypothesis is required as only 5 or 6 cases of Kimura disease have been evaluated for this viral infection. Proliferative squamous metaplasia occurring in parotid gland lesions of Kimura disease is rare and may complicate the diagnostic imaging and pathological diagnosis.
Collapse
Affiliation(s)
- Kenji Yorita
- Department of Diagnostic Pathology, Japanese Red Cross Kochi Hospital, 1-4-63-11, Hadaminami-machi, Kochi-shi, Kochi, 780-8562, Japan
- Department of Diagnostic Pathology, Kochi University Hospital, Kohasu, Oko-cho, Nankoku-shi, Kochi, 783-8505, Japan
- Corresponding author.
| | - Tatsuya Fujii
- Department of Otorhinolaryngology, JA Kochi Hospital, 526-1, Nakano, Aza, Myouken, Nankoku-shi, Kochi, 783-8509, Japan
| | - Toshitaka Nagao
- Department of Anatomic Pathology, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan
| | - Ichiro Murakami
- Department of Diagnostic Pathology, Kochi University Hospital, Kohasu, Oko-cho, Nankoku-shi, Kochi, 783-8505, Japan
- Department of Pathology, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku-shi, Kochi, 783-8505, Japan
| | - Yumiko Hashida
- Department of Microbiology and Infection, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku-shi, Kochi, 783-8505, Japan
| | - Tomonori Higuchi
- Department of Microbiology and Infection, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku-shi, Kochi, 783-8505, Japan
| | - Masanori Daibata
- Department of Microbiology and Infection, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku-shi, Kochi, 783-8505, Japan
| | - Makoto Toi
- Department of Diagnostic Pathology, Kochi University Hospital, Kohasu, Oko-cho, Nankoku-shi, Kochi, 783-8505, Japan
| | - Yoshiyuki Ayada
- Department of Pathology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, 2-5-1, Shikata-cho, Kita-ku, Okayama, 700-8558, Japan
| | - Takuro Igawa
- Department of Pathology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, 2-5-1, Shikata-cho, Kita-ku, Okayama, 700-8558, Japan
| |
Collapse
|
6
|
Higuchi T, Hashida Y, Matsuo K, Kitahata K, Ujihara T, Murakami I, Nakayama T, Daibata M. EBV-positive pyothorax-associated lymphoma expresses CXCL9 and CXCL10 chemokines that attract cytotoxic lymphocytes via CXCR3. Cancer Sci 2023. [PMID: 36898851 DOI: 10.1111/cas.15782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2022] [Revised: 03/01/2023] [Accepted: 03/06/2023] [Indexed: 03/12/2023] Open
Abstract
Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma associated with chronic inflammation (DLBCL-CI) develops in the setting of long-standing inflammation. This type of lymphoma may have specific expression profiles of chemokines involved in the pathogenesis of DLBCL-CI. EBV-positive pyothorax-associated lymphoma (PAL) is a prototype of DLBCL-CI and represents a valuable model for the study of this disease category. Using a panel of PAL cell lines, we found that PAL cells expressed and secreted C-X-C motif chemokine ligands 9 and 10 (CXCL9 and CXCL10), the ligands of CXCR3, in contrast to EBV-negative DLBCL cell lines, which did not. Culture supernatants from PAL cell lines attracted CXCR3-expressing CD4+ T cells, CD8+ T cells, and CD56+ natural killer cells from human peripheral blood mononuclear cells. PAL cells injected into mice also attracted CXCR3-positive cytotoxic lymphocytes that expressed interferon-γ. The expression of CXCL9 and CXCL10 was detected in PAL tumor biopsy samples from patients, and CXCR3-positive lymphocytes were abundant in the tissue samples. Collectively, these findings suggest that CXCL9 and CXCL10 are produced by PAL cells and can elicit cytotoxic responses via CXCR3. This chemokine system is also likely to contribute to tissue necrosis, which is a signature histological feature of DLBCL-CI. Further studies are warranted to determine whether the CXCL9-CXCL10/CXCR3 axis exerts antitumor effects in DLBCL-CI.
Collapse
Affiliation(s)
- Tomonori Higuchi
- Department of Microbiology and Infection, Kochi Medical School, Kochi University, Nankoku, Japan
| | - Yumiko Hashida
- Department of Microbiology and Infection, Kochi Medical School, Kochi University, Nankoku, Japan
| | - Kazuhiko Matsuo
- Division of Chemotherapy, Kindai University Faculty of Pharmacy, Higashi-Osaka, Japan
| | - Kosuke Kitahata
- Division of Chemotherapy, Kindai University Faculty of Pharmacy, Higashi-Osaka, Japan
| | - Takako Ujihara
- Department of Microbiology and Infection, Kochi Medical School, Kochi University, Nankoku, Japan
- Science Research Center, Kochi University, Nankoku, Japan
| | - Ichiro Murakami
- Department of Pathology, Kochi Medical School, Kochi University, Nankoku, Japan
| | - Takashi Nakayama
- Division of Chemotherapy, Kindai University Faculty of Pharmacy, Higashi-Osaka, Japan
| | - Masanori Daibata
- Department of Microbiology and Infection, Kochi Medical School, Kochi University, Nankoku, Japan
| |
Collapse
|
7
|
Hayashi Y, Yamamoto Y, Murakami I. Fascin expression persists with fibronectin in embryonic rat hepatoblasts. Med Mol Morphol 2022; 55:100-109. [PMID: 35048195 DOI: 10.1007/s00795-021-00311-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Accepted: 12/09/2021] [Indexed: 11/30/2022]
Abstract
Both fascin and fibronectin are known to play important roles in cell adhesion and migration. They are noted as tumor markers or inhibiting target for tumor treatment. In this study, embryonic rat livers were obtained to examine the expression of fascin and fibronectin during liver development. Then, the effect of fibronectin on fascin expression was investigated. At embryonic day (ED) 10.5, when the foregut endoderm began to form the liver bud and spread into the septum transversum, fibrous extracellular matrix was observed between the space where the liver bud and the septum transversum merged. At ED11.5, fibronectin was observed surrounding the cluster of fascin-positive hepatoblasts. At ED13.5, hematopoietic cells emerged and both fibronectin and fascin expression started to decline. Fascin and fibronectin appeared temporarily and disappeared by ED 14.5. Their expression was chronologically synchronized. Subsequently, the effect of fibronectin on fascin was examined by cultivation of hepatoblasts that were isolated from the ED13.5 rat liver. As a result, with fibronectin, fascin was positive in most hepatoblasts, although, without fibronectin, fascin expression was remarkably declined. Presently, there are few studies about the relationship between fascin and fibronectin. Our findings suggest that fibronectin could regulate fascin expression in rat hepatoblasts.
Collapse
Affiliation(s)
- Yoshihiro Hayashi
- Equipment of Support Planning Office, Kochi University, 185-1, Oko-cho, Kohasu, Nankoku, Kochi, 783-8505, Japan.,Department of Pathology, School of Medicine, Kochi University, 185-1, Oko-cho, Kohasu, Nankoku, Kochi, 783-8505, Japan
| | - Yumiko Yamamoto
- Department of Diagnostic Pathology, Kochi University Hospital, 185-1, Oko-cho, Kohasu, Nankoku, Kochi, 783-8505, Japan.
| | - Ichiro Murakami
- Department of Diagnostic Pathology, Kochi University Hospital, 185-1, Oko-cho, Kohasu, Nankoku, Kochi, 783-8505, Japan.,Department of Pathology, School of Medicine, Kochi University, 185-1, Oko-cho, Kohasu, Nankoku, Kochi, 783-8505, Japan
| |
Collapse
|
8
|
Yamamoto Y, Hayashi Y, Sakaki H, Murakami I. Evaluation of Clinical and Immunohistochemical Factors Relating to Melanoma Metastasis: Potential Roles of Nestin and Fascin in Melanoma. Diagnostics (Basel) 2022; 12:diagnostics12010219. [PMID: 35054386 PMCID: PMC8774891 DOI: 10.3390/diagnostics12010219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2021] [Revised: 01/12/2022] [Accepted: 01/13/2022] [Indexed: 02/01/2023] Open
Abstract
For melanoma treatment, an early diagnosis and a complete resection of the primary tumor is essential. In addition, detection of factors that may be related to metastasis is indispensable. A total of 30 Japanese patients with Stage I or II melanoma, diagnosed according to the classification of the American Joint Committee on Cancer, are included in this study. Clinical background (sex, onset age, primary tumor area, existence of remaining cancer cells at the resected tissue margin, and treatment after the primary surgery) and immunohistochemical staining (Nestin and Fascin) on the resected tissue were examined to detect factors statistically related to metastasis. The analysis result has shown that older onset age and positive immunohistochemical expressions of Nestin and Fascin are statistically related to metastasis. To facilitate meticulous observation of Nestin and Fascin expression at different timing (e.g., onset and metastasis), double immunofluorescence staining was performed. Nestin is a class VI intermediate filament protein, initially detected in neural stem cells. Fascin is an actin-bundling protein which regulates cell adhesion, migration and invasion. Nestin and Fascin are suggested to relate to melanoma metastasis, however, the potential role of Fascin is controversial. Analysis of variations in Fascin expression detected in this study may contribute to further investigations concerning potential roles of Fascin for progression of melanoma. This is the first study to report double immunofluorescent staining of Nestin and Fascin in melanoma. Nestin and Fascin double-positive melanoma cells were detected.
Collapse
Affiliation(s)
- Yumiko Yamamoto
- Department of Diagnostic Pathology, Kochi University Hospital, Kochi University, 185-1, Kohasu, Oko-cho, Nankoku 783-8505, Japan;
- Correspondence: ; Tel.: +81-88-880-2330
| | - Yoshihiro Hayashi
- Equipment of Support Planning Office, Kochi University, 185-1, Kohasu, Oko-cho, Nankoku 783-8505, Japan;
- Department of Pathology, School of Medicine, Kochi University, 185-1, Kohasu, Oko-cho, Nankoku 783-8505, Japan
| | - Hideyuki Sakaki
- Department of Nutritional Sciences for Well-Being Health, Kansai University of Welfare Sciences, 3-11-1, Asahigaoka, Kahsihara 582-0026, Japan;
| | - Ichiro Murakami
- Department of Diagnostic Pathology, Kochi University Hospital, Kochi University, 185-1, Kohasu, Oko-cho, Nankoku 783-8505, Japan;
- Department of Pathology, School of Medicine, Kochi University, 185-1, Kohasu, Oko-cho, Nankoku 783-8505, Japan
| |
Collapse
|
9
|
Murakami I, Hashida Y, Higuchi T, Daibata M. [Histiocytosis and virus: Merkel cell polyomavirus]. Rinsho Ketsueki 2022; 63:383-392. [PMID: 35662161 DOI: 10.11406/rinketsu.63.383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Histiocytosis is classified based on proliferating histiocyte-like cells. Langerhans cell histiocytosis (LCH) has several subtypes with various outcomes, from spontaneous to fatal regression, and these subtypes had been managed as different diseases. However, these different names of disease were unified to one disease named histiocytosis X since they are pathologically identical. Presently, LCH has been used as a unified name because proliferating cells have the characteristics of Langerhans cells. Since then, clonality and BRAF mutations have been reported, and their neoplastic characteristics has become clear; however, explaining its various subtypes is difficult with only the neoplastic character. Various relationships/correlations are also known between inflammatory factors and LCH subtypes. We have pointed out that the Merkel cell polyomavirus may be involved in LCH development and LCH is a disease with both neoplastic and reactive characters, that is, "a disease in which abnormal Langerhans-like cells with neoplastic character overreact to some triggers."
Collapse
Affiliation(s)
- Ichiro Murakami
- Department of Pathology, Kochi Medical School, Kochi University
| | - Yumiko Hashida
- Department of Microbiology and Infection, Kochi Medical School, Kochi University
| | - Tomonori Higuchi
- Department of Microbiology and Infection, Kochi Medical School, Kochi University
| | - Masanori Daibata
- Department of Microbiology and Infection, Kochi Medical School, Kochi University
| |
Collapse
|
10
|
Nishimori T, Higuchi T, Hashida Y, Ujihara T, Taniguchi A, Ogasawara F, Kitamura N, Murakami I, Kojima K, Daibata M. Development of a novel cell line-derived xenograft model of primary herpesvirus 8-unrelated effusion large B-cell lymphoma and antitumor activity of birabresib in vitro and in vivo. Cancer Med 2021; 10:8976-8987. [PMID: 34821060 PMCID: PMC8683535 DOI: 10.1002/cam4.4394] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2021] [Revised: 10/06/2021] [Accepted: 10/07/2021] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Primary human herpesvirus 8 (HHV8)-unrelated effusion large B-cell lymphoma is a clinical disease entity distinct from HHV8-positive primary effusion lymphoma (PEL). However, the lack of experimental HHV8-unrelated effusion large B-cell lymphoma models continues to hinder the pathophysiologic and therapeutic investigations of this disorder. METHODS The lymphoma cells were obtained from the pleural effusion of a patient with primary HHV8-unrelated effusion large B-cell lymphoma and cultured in vitro. RESULTS We established a novel HHV8-unrelated effusion large B-cell lymphoma cell line, designated Pell-1, carrying a c-MYC rearrangement with features distinct from those of HHV8-positive PEL. Moreover, we developed an HHV8-unrelated effusion large B-cell lymphoma cell line-derived xenograft model. Pell-1 cells induced profuse lymphomatous ascites and subsequently formed intra-abdominal tumors after intraperitoneal implantation into irradiated nonobese diabetic/severe combined immunodeficient mice. Thus, this xenograft mouse model mimicked the clinical phenomena observed in patients and recapitulated the sequential stages of aggressive HHV8-unrelated effusion large B-cell lymphoma. The bromodomain and extraterminal domain (BET) inhibitors JQ1 and birabresib (MK-8628/OTX015) reduced the proliferation of Pell-1 cells in vitro through the induction of cell cycle arrest and apoptosis. The antitumor effect of BET inhibition was also demonstrated in vivo, as birabresib significantly reduced ascites and suppressed tumor progression without apparent adverse effects in the xenografted mice. CONCLUSION These preclinical findings suggest the therapeutic potential of targeting c-MYC through BET inhibition in HHV8-unrelated effusion large B-cell lymphoma.
Collapse
Affiliation(s)
- Tomohiro Nishimori
- Department of Microbiology and InfectionKochi Medical SchoolKochi UniversityNankokuJapan
| | - Tomonori Higuchi
- Department of Microbiology and InfectionKochi Medical SchoolKochi UniversityNankokuJapan
| | - Yumiko Hashida
- Department of Microbiology and InfectionKochi Medical SchoolKochi UniversityNankokuJapan
| | - Takako Ujihara
- Department of Microbiology and InfectionKochi Medical SchoolKochi UniversityNankokuJapan
- Science Research CenterKochi UniversityNankokuJapan
| | - Ayuko Taniguchi
- Department of Microbiology and InfectionKochi Medical SchoolKochi UniversityNankokuJapan
- Department of HematologyKochi Medical SchoolKochi UniversityNankokuJapan
| | - Fumiya Ogasawara
- Department of Microbiology and InfectionKochi Medical SchoolKochi UniversityNankokuJapan
- Department of HematologyKochi Medical SchoolKochi UniversityNankokuJapan
| | - Naoya Kitamura
- Department of Oral and Maxillofacial SurgeryKochi Medical SchoolKochi UniversityNankokuJapan
| | - Ichiro Murakami
- Department of PathologyKochi Medical SchoolKochi UniversityNankokuJapan
| | - Kensuke Kojima
- Department of HematologyKochi Medical SchoolKochi UniversityNankokuJapan
| | - Masanori Daibata
- Department of Microbiology and InfectionKochi Medical SchoolKochi UniversityNankokuJapan
| |
Collapse
|
11
|
Togitani K, Iguchi M, Asagiri T, Ogasawara F, Murakami I, Kojima K. Glucocorticoid-induced redistribution lymphocytosis in mantle cell lymphoma with hyaline vascular Castleman disease-like features. J Clin Exp Hematop 2021; 62:46-51. [PMID: 34707036 PMCID: PMC9010492 DOI: 10.3960/jslrt.21024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
We report a case of mantle cell lymphoma mimicking Castleman disease. A 76-year-old man presented with generalized lymphadenopathy, splenomegaly, anemia, polyclonal gammopathy, and pulmonary infiltrations. Lymph node biopsy revealed histological features of hyaline vascular Castleman disease. Treatment with prednisolone induced lymphocytosis with immunophenotypic and genetic features of mantle cell lymphoma. A detailed immunohistochemical study of the lymph node demonstrated a mantle cell lymphoma-mantle zone growth pattern. Glucocorticoid-induced distribution lymphocytosis has not been reported in mantle cell lymphoma. Careful observation of circulating lymphocytes during steroid treatment may enable diagnosis of the underlying occult lymphoma in a subset of patients exhibiting clinical manifestations of Castleman disease.
Collapse
Affiliation(s)
- Kazuto Togitani
- Department of Hematology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan
| | - Mitsuko Iguchi
- Department of Pathology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan
| | - Tadashi Asagiri
- Department of Laboratory Medicine, Kochi Medical School Hospital, Nankoku, Kochi, Japan
| | - Fumiya Ogasawara
- Department of Hematology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan
| | - Ichiro Murakami
- Department of Pathology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan
| | - Kensuke Kojima
- Department of Hematology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan
| |
Collapse
|
12
|
Tsujii S, Serada S, Fujimoto M, Uemura S, Namikawa T, Nomura T, Murakami I, Hanazaki K, Naka T. Glypican-1 Is a Novel Target for Stroma and Tumor Cell Dual-Targeting Antibody-Drug Conjugates in Pancreatic Cancer. Mol Cancer Ther 2021; 20:2495-2505. [PMID: 34583978 DOI: 10.1158/1535-7163.mct-21-0335] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2021] [Revised: 07/21/2021] [Accepted: 09/20/2021] [Indexed: 02/05/2023]
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a stroma-rich cancer. Extracellular matrix proteins produced by cancer-associated fibroblasts (CAFs) found in tumor stroma that impedes effective delivery of chemotherapeutic agents results in poor response in patients with PDAC. Previously, our group reported that glypican-1 (GPC1) was overexpressed in human PDAC and negatively correlated with patient survival. Immunohistochemical analysis of 25 patients with PDAC tumor specimens revealed elevated expression of GPC1 in stromal cells and pancreatic cancer cells in 80% of patients. Interestingly, GPC1 was expressed on CAFs in PDAC. We generated a GPC1 antibody-drug conjugate conjugated with monomethyl auristatin E [GPC1-ADC(MMAE)] and evaluated its preclinical antitumor activity by targeting GPC1-positive CAF and cancer cells in PDAC. GPC1-ADC(MMAE) inhibited the growth of GPC1-positive PDAC cell lines in vitro. Furthermore, GPC1-ADC(MMAE) showed a potent antitumor effect in the PDAC patient-derived tumor xenograft (PDX) model against GPC1-positive CAF and heterogeneous GPC1-expressing cancer cells. Notably, GPC1-ADC(MMAE) showed robust preclinical efficacy against GPC1 in a stroma-positive/cancer-negative PDAC PDX model. GPC1-ADC(MMAE) was delivered and internalized to CAFs. Although apoptosis was not observed in CAFs, the released MMAE from CAFs via MDR-1 induced apoptosis of cancer cells neighboring CAFs and efficiently inhibited PDAC tumor growth. GPC1-ADC(MMAE) exhibited potent and unique antitumor activity in GPC1-positive PDAC PDX models, which suggests that GPC1 is a novel therapeutic target in PDAC and other stromal GPC1-positive solid tumors. These findings show that targeting GPC1 on CAF using GPC1-ADC(MMAE) is a useful approach in case of stroma-rich tumors such as PDAC.
Collapse
Affiliation(s)
- Shigehiro Tsujii
- Department of Surgery, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan.,Department of Clinical Immunology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan
| | - Satoshi Serada
- Department of Clinical Immunology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan. .,Institute for Biomedical Sciences Molecular Pathophysiology, Iwate Medical University, Yahaba, Iwate, Japan
| | - Minoru Fujimoto
- Department of Clinical Immunology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan.,Division of Allergy and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Iwate, Japan
| | - Sunao Uemura
- Department of Surgery, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan
| | - Tsutomu Namikawa
- Department of Surgery, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan
| | - Taisei Nomura
- Animal Models of Human Diseases, National Institute of Biomedical Innovation, Health and Nutrition, Ibaraki, Osaka, Japan
| | - Ichiro Murakami
- Department of Pathology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan
| | - Kazuhiro Hanazaki
- Department of Surgery, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan
| | - Tetsuji Naka
- Department of Clinical Immunology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan. .,Institute for Biomedical Sciences Molecular Pathophysiology, Iwate Medical University, Yahaba, Iwate, Japan.,Division of Allergy and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Iwate, Japan
| |
Collapse
|
13
|
Yashige K, Kataoka TR, Yamada Y, Maeda H, Oji-Tsujimura M, Yamamoto T, Takei Y, Moriyoshi K, Ono K, Kaku Y, Tabata T, Murakami I, Nakamine H, Haga H. The Expression of Insulin-Like Growth Factor 2 Messenger RNA-Binding Protein 3 in Langerhans Cell Histiocytosis and Langerhans Cell Sarcoma. TOHOKU J EXP MED 2021; 255:27-31. [PMID: 34497165 DOI: 10.1620/tjem.255.27] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Langerhans cell neoplasms, which include Langerhans cell histiocytosis and Langerhans cell sarcoma, are tumors that originate from dendritic cells. Langerhans cell sarcoma is defined as a high-grade neoplasm with overtly malignant cytological features and the Langerhans cell-like phenotype, and generally has a poorer prognosis and more aggressive phenotype than Langerhans cell histiocytosis. Insulin-like growth factor 2 messenger RNA-binding protein 3 (IGF2BP3 or IMP3) is an oncofetal protein that is expressed in various cancer types; its expression is often associated with a poor prognosis and aggressive phenotype. Here, we used immunohistochemistry to evaluate IGF2BP3 expression in Langerhans cell neoplasms. IGF2BP3 expression was scored as negative (< 1%) or positive (≥ 1%) by immunohistochemistry. All 4 patients with Langerhans cell sarcoma (100%) and 6 of 22 pediatric (age < 18 years) patients with Langerhans cell histiocytosis (27.3%) had positive results for IGF2BP3; however, 16 of 22 pediatric patients with Langerhans cell histiocytosis (72.7%) and all 15 adult (age ≥ 18 years) patients with Langerhans cell histiocytosis (100%) had a negative result. Among patients with Langerhans cell histiocytosis, IGF2BP3 expression was independent of sex, location, prognosis, and BRAF V600E staining results. Taken together, these results indicate that IGF2BP3 expression may be a helpful marker for distinguishing Langerhans cell sarcoma from Langerhans cell histiocytosis in adult patients.
Collapse
Affiliation(s)
- Konomi Yashige
- Department of Diagnostic Pathology, Kyoto University Hospital.,Department of Diagnostic Pathology, Hyogo Prefectural Amagasaki General Medical Center
| | - Tatsuki R Kataoka
- Department of Diagnostic Pathology, Kyoto University Hospital.,Department of Pathology, Iwate Medical University
| | - Yosuke Yamada
- Department of Diagnostic Pathology, Kyoto University Hospital
| | - Hirona Maeda
- Department of Diagnostic Pathology, Kyoto University Hospital
| | | | - Tetsurou Yamamoto
- Department of Diagnostic Pathology, Hyogo Prefectural Amagasaki General Medical Center
| | - Yusuke Takei
- Department of Diagnostic Pathology, Kyoto University Hospital.,Department of Diagnostic Pathology, Saiseikai Noe Hospital
| | - Koki Moriyoshi
- Department of Diagnostic Pathology, Kyoto University Hospital.,Department of Diagnostic Pathology, Kyoto Medical Center
| | - Kazuo Ono
- Department of Pathology, Japan Red Cross Society Wakayama Medical Center
| | - Yo Kaku
- Deparment of Dermatology, Kyoto University Hospital.,Department of Dermatology, Faculty of Medicine, Kagawa University
| | - Tetsuya Tabata
- Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
| | - Ichiro Murakami
- Department of Pathology, Kochi Medical School, Kochi University
| | | | - Hironori Haga
- Department of Diagnostic Pathology, Kyoto University Hospital
| |
Collapse
|
14
|
Yamamoto Y, Hayashi Y, Sakaki H, Murakami I. Fascin-1 is associated with recurrence in solitary fibrous tumor/hemangiopericytoma. Mol Clin Oncol 2021; 15:199. [PMID: 34462655 PMCID: PMC8375015 DOI: 10.3892/mco.2021.2361] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Accepted: 07/15/2021] [Indexed: 02/03/2023] Open
Abstract
Fascin-1, an actin-bundling protein, is associated with poor prognosis in patients with various types of human carcinoma. However, research is limited on the role of fascin-1 in sarcoma. Solitary fibrous tumor (SFT) and hemangiopericytoma (HPC) are rare sarcomas derived from the mesenchyme. Although the prognosis of SFT/HPC is generally favorable, fatalities are possible with repeated recurrence and distant metastasis. The current study included a total of 20 Japanese patients, who were diagnosed with SFT/HPC and underwent surgery at Kochi University Hospital from January 2000 to December 2019. The statistical relationship between recurrence and the following variables were examined: Sex, age of onset, tumor origin, tumor size, necrosis, mitosis ≥1/10 high power field (HPF; magnification, x400), Ki-67 >5% and Fascin-1. A significant association was determined between recurrence and necrosis, mitosis ≥1/10 HPF (magnification, x400), Ki-67 >5%, and Fascin-1 ≥‘strongly positive’ (P<0.05). The results demonstrated that Fascin-1 immunostaining may be a highly effective and useful evaluation factor for predicting poor prognosis in patients with SFT/HPC, a fatal sarcoma of humans.
Collapse
Affiliation(s)
- Yumiko Yamamoto
- Department of Diagnostic Pathology, Kochi University Hospital, Kochi University, Nankoku, Kochi 783-8505, Japan
| | - Yoshihiro Hayashi
- Equipment of Support Planning Office, Kochi University, Nankoku, Kochi 783-8505, Japan
| | - Hideyuki Sakaki
- Department of Nutritional Sciences for Well-being Health, Kansai University of Welfare Sciences, Kashiwa, Osaka 582-0026, Japan
| | - Ichiro Murakami
- Department of Diagnostic Pathology, Kochi University Hospital, Kochi University, Nankoku, Kochi 783-8505, Japan.,Department of Pathology, School of Medicine, Kochi University, Nankoku, Kochi 783-8505, Japan
| |
Collapse
|
15
|
Kobayashi S, Fukuhara H, Yamamoto S, Karashima T, Iguchi M, Murakami I, Inoue K. A case of mixed tumor formed by metastasis of urothelial carcinoma and malignant lymphoma to the same lymph nodes. IJU Case Rep 2021; 4:294-297. [PMID: 34497987 PMCID: PMC8413221 DOI: 10.1002/iju5.12329] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2021] [Accepted: 05/20/2021] [Indexed: 12/09/2022] Open
Abstract
INTRODUCTION Mixed tumor in the same lymph nodes is extremely rare and no previous reports have described mixed tumor comprising urothelial carcinoma and malignant lymphoma. CASE PRESENTATION A 71-year-old woman visited a local clinic with a main complaint of hematuria. Imaging revealed right hydronephrosis and a mid-ureter tumor shadow. Positron emission tomography-computed tomography showed high uptake of fluorodeoxyglucose in para-aortic lymph nodes. Abdominal para-aortic lymph node biopsy was performed. Pathology showed urothelial carcinoma and malignant lymphoma in the same lymph nodes, where a mixed tumor was diagnosed. CONCLUSION We encountered a case of mixed tumor of urothelial carcinoma and Hodgkin lymphoma, which metastasized to the same tissues.
Collapse
Affiliation(s)
- Shu Kobayashi
- Departments ofDepartment ofUrologyKochi Medical SchoolNankokuJapan
| | - Hideo Fukuhara
- Departments ofDepartment ofUrologyKochi Medical SchoolNankokuJapan
| | | | | | | | | | - Keiji Inoue
- Departments ofDepartment ofUrologyKochi Medical SchoolNankokuJapan
| |
Collapse
|
16
|
Hashida Y, Higuchi T, Matsumoto S, Iguchi M, Murakami I, Hyodo M, Daibata M. Prognostic significance of human papillomavirus 16 viral load level in patients with oropharyngeal cancer. Cancer Sci 2021; 112:4404-4417. [PMID: 34382311 PMCID: PMC8486212 DOI: 10.1111/cas.15105] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2021] [Revised: 08/01/2021] [Accepted: 08/09/2021] [Indexed: 12/16/2022] Open
Abstract
Human papillomavirus (HPV) infection in patients with oropharyngeal squamous cell carcinoma (OPSCC) is a major determinant for better prognosis. However, there remain HPV‐positive patients who have poor outcomes. The stratification strategy for detecting high‐risk patients among those with HPV‐positive OPSCC has not been well delineated, especially for Asian patients. We undertook a retrospective cohort study on the survival rate of 89 Japanese patients diagnosed with primary OPSCC. The tumors were concurrently analyzed for the presence of HPV E6 DNA/mRNA, viral DNA load, p16 expression, viral physical status, and viral variant lineage. Human papillomavirus 16 viral DNA was found in 45 (51%) OPSCCs. Human papillomavirus 16 DNA‐positive OPSCCs with higher viral load (classified as HPV16 DNA‐medium/high OPSCCs) showed significantly favorable overall survival and progression‐free survival compared with HPV16 DNA‐positive OPSCCs with lower viral load (<10 copies/cell; HPV16 DNA‐low OPSCCs) and HPV16 DNA‐negative OPSCCs. E6 mRNA expression was observed in all HPV16 DNA‐medium/high OPSCCs but not in HPV16 DNA‐low OPSCCs. Notably, p16‐positive and HPV16 DNA‐negative/low OPSCCs showed significantly worse survival than p16‐positive and HPV16 DNA‐medium/high OPSCCs and resembled HPV‐unrelated OPSCCs with regard to survival and risk factor profile. Although not significant, a trend toward shorter survival was observed for HPV16‐integrated OPSCCs. Phylogenetic analysis revealed two major types of HPV16 variants termed Asian (A4) and European (A1/A2/A3) variants, but no difference in survival between these variants was observed. Altogether, these findings suggest that HPV viral load is a potentially informative factor for more accurate risk stratification of patients with OPSCC.
Collapse
Affiliation(s)
- Yumiko Hashida
- Department of Microbiology and Infection, Kochi Medical School, Kochi University, Nankoku, Japan
| | - Tomonori Higuchi
- Department of Microbiology and Infection, Kochi Medical School, Kochi University, Nankoku, Japan
| | - Shuichi Matsumoto
- Department of Otolaryngology, Head and Neck Surgery, Kochi Medical School, Kochi University, Nankoku, Japan
| | - Mitsuko Iguchi
- Department of Pathology, Kochi Medical School, Kochi University, Nankoku, Japan
| | - Ichiro Murakami
- Department of Pathology, Kochi Medical School, Kochi University, Nankoku, Japan
| | - Masamitsu Hyodo
- Department of Otolaryngology, Head and Neck Surgery, Kochi Medical School, Kochi University, Nankoku, Japan
| | - Masanori Daibata
- Department of Microbiology and Infection, Kochi Medical School, Kochi University, Nankoku, Japan
| |
Collapse
|
17
|
Munekage E, Serada S, Tsujii S, Yokota K, Kiuchi K, Tominaga K, Fujimoto M, Kanda M, Uemura S, Namikawa T, Nomura T, Murakami I, Hanazaki K, Naka T. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma. Neoplasia 2021; 23:939-950. [PMID: 34332450 PMCID: PMC8340053 DOI: 10.1016/j.neo.2021.07.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2021] [Revised: 07/10/2021] [Accepted: 07/12/2021] [Indexed: 02/08/2023]
Abstract
An antibody-drug conjugate (ADC) is a promising therapeutic modality because selective and effective delivery of an anti-cancer drug is achieved by drug-conjugated antibody-targeting cancer antigen. Glypican 1 (GPC1) is highly expressed in malignant tumors, including pancreatic ductal adenocarcinoma (PDAC) and esophageal squamous cell carcinoma (ESCC). Herein, we describe the usefulness of GPC1-targeting ADC. Humanized anti-GPC1 antibody (clone T2) was developed and conjugated with monomethyl auristatin E (MMAE) via maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PABC) linkers (humanized GPC1-ADC[MMAE]). Humanized GPC1-ADC(MMAE) inhibited the growth of GPC1-positive PDAC and ESCC cell lines via inducing cycle arrest in the G2/M phase and apoptosis in vitro. The binding activity of humanized GPC1-ADC(MMAE) with GPC1 was comparable with that of the unconjugated anti-GPC1 antibody. The humanized GPC1-ADC(MMAE) was effective in GPC1-positive BxPC-3 subcutaneously xenografted mice but not in GPC1-negative BxPC-3-GPC1-KO xenografted mice. To assess the bystander killing activity of the humanized GPC1-ADC(MMAE), a mixture of GPC1-positive BxPC-3 and GPC1-negative BxPC-3-GPC1-KO-Luc cells were subcutaneously inoculated, and a heterogenous GPC1-expressing tumor model was developed. The humanized GPC1-ADC(MMAE) inhibited the tumor growth and decreased the luciferase signal, measured with an in vivo imaging system (IVIS), which suggests that the suppression of the BxPC-3-GPC1-KO-Luc population. The humanized GPC1-ADC(MMAE) also inhibited the established liver metastases of BxPC-3 cells and significantly improved the overall survival of the mice. It exhibited a potent antitumor effect on the GPC1-positive PDAC and ESCC patient-derived xenograft (PDX) models. Our preclinical data demonstrate that GPC1 is a promising therapeutic target for ADC.
Collapse
Affiliation(s)
- Eri Munekage
- Department of Surgery, Kochi University, Nankoku, Kochi, Japan; Department of Clinical Immunology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan
| | - Satoshi Serada
- Department of Clinical Immunology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan; Institute for Biomedical Sciences Molecular Pathophysiology, Iwate Medical University, Yahaba, Iwate, Japan.
| | - Shigehiro Tsujii
- Department of Surgery, Kochi University, Nankoku, Kochi, Japan; Department of Clinical Immunology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan
| | - Keiichiro Yokota
- Department of Surgery, Kochi University, Nankoku, Kochi, Japan; Department of Clinical Immunology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan
| | - Keita Kiuchi
- Department of Medical course, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan
| | - Kenji Tominaga
- Department of Medical course, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan
| | - Minoru Fujimoto
- Department of Clinical Immunology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan; Division of Allergy and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Iwate, Japan
| | - Mizuki Kanda
- Institute for Biomedical Sciences Molecular Pathophysiology, Iwate Medical University, Yahaba, Iwate, Japan
| | - Sunao Uemura
- Department of Surgery, Kochi University, Nankoku, Kochi, Japan
| | | | - Taisei Nomura
- Animal Models of Human Diseases, National Institute of Biomedical Innovation, Health and Nutrition, Ibaraki, Osaka, Japan
| | - Ichiro Murakami
- Department of Pathology, School of Medicine, Kochi University, Nankoku, Kochi, Japan
| | | | - Tetsuji Naka
- Department of Clinical Immunology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan; Institute for Biomedical Sciences Molecular Pathophysiology, Iwate Medical University, Yahaba, Iwate, Japan; Division of Allergy and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Iwate, Japan.
| |
Collapse
|
18
|
Yokota K, Serada S, Tsujii S, Murakami I, Hanazaki K, Naka T. Abstract 1315: Antibody-drug conjugate targeting glypican-1 inhibits tumor growth and tumor angiogenesis for glypican-1 positive cholangiocarcinoma. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-1315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Cholangiocarcinoma (CCA) is one of highly malignant cancers. Systemic chemotherapy is used in many patients, however, there are few chemotherapy options, and their prognosis are poor. Therefore, it is necessary to develop new treatments. We have identified glypican-1 (GPC1) as a novel cancer antigen and reported that enhanced expression of GPC1 in esophageal squamous cell carcinoma and pancreatic cancer is significantly associated with poorer prognosis (Hara, Naka, et al. Br J Cancer. 2016, Nishigaki, Naka, et al. Br J Cancer. 2020). GPC1 is a heparan sulfate proteoglycan that is linked to the cell surface by a glycosylphosphatidylinositol anchor and promotes tumor growth, metastasis, and invasion by acting as a coreceptor, enhancing various signaling pathways. We recently identified that the expression of GPC1 was increased in cholangiocarcinoma. The present study aimed to develop a new therapy for cholangiocarcinoma using an antibody-drug conjugate (ADC) targeting glypican-1 (GPC1). Expression of GPC1 was evaluated in resected cholangiocarcinoma specimens and cell lines. GPC1 knockout cell was established from GPC1-positive cholangiocarcinoma cell line. The antitumor effect of monomethyl auristatin F conjugated GPC1-ADC was investigated in vitro and in vivo. GPC1 was highly expressed in cholangiocarcinoma cells and tissues. Immunohistochemical analysis of 49 extrahepatic cholangiocarcinoma patients revealed that 23 patients (47%) were high expression of GPC1, 24 patients (49%) were low expression of GPC1 and 2 patients (4%) were GPC1 negative. High-expression group demonstrated significantly poorer prognosis compared with the low-expression group in terms of disease-free survival and overall survival (p < 0.05). GPC1 was also expressed in tumor vessels of cholangiocarcinoma, but not on the vessels of nontumor tissues. Monomethyl auristatin F-conjugated GPC1-ADC significantly inhibited tumor growth against GPC1-positive cholangiocarcinoma cells in vitro and in vivo. In a GPC1 knockout xenograft model, GPC1-ADC partially inhibited tumor growth. Vascular endothelial cells in tumor tissues of GPC1-negative xenograft mice expressed GPC1 and were arrested in the G2/M phase of cell cycle by GPC1-ADC. In the present study, GPC1-ADC inhibits tumor growth and tumor angiogenesis for glypican-1 positive cholangiocarcinoma. Our preclinical data demonstrated GPC1-ADC as a promising strategy for GPC1-positive cholangiocarcinoma.
Citation Format: Keiichiro Yokota, Satoshi Serada, Shigehiro Tsujii, Ichiro Murakami, Kazuhiro Hanazaki, Tetsuji Naka. Antibody-drug conjugate targeting glypican-1 inhibits tumor growth and tumor angiogenesis for glypican-1 positive cholangiocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1315.
Collapse
|
19
|
Yokota K, Serada S, Tsujii S, Toya K, Takahashi T, Matsunaga T, Fujimoto M, Uemura S, Namikawa T, Murakami I, Kobayashi S, Eguchi H, Doki Y, Hanazaki K, Naka T. Anti-Glypican-1 Antibody-drug Conjugate as Potential Therapy Against Tumor Cells and Tumor Vasculature for Glypican-1-Positive Cholangiocarcinoma. Mol Cancer Ther 2021; 20:1713-1722. [PMID: 34224365 DOI: 10.1158/1535-7163.mct-21-0015] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2021] [Revised: 02/27/2021] [Accepted: 05/27/2021] [Indexed: 02/05/2023]
Abstract
Cholangiocarcinoma is a highly malignant cancer. Many patients need systemic chemotherapy to prevent tumor development and recurrence; however, their prognosis is poor due to the lack of effective therapy. Therefore, a new treatment option is urgently required. We recently identified glypican-1 (GPC1) as a novel cancer antigen of esophageal squamous cell carcinoma. We also demonstrated the efficacy and safety of GPC1-targeted ADC (GPC1-ADC) conjugating anti-GPC1 mAb possessing high internalization activity with monomethyl auristatin F (MMAF), which is a potent tubulin polymerizing inhibitor. In this study, we confirmed that GPC1 was highly expressed in cholangiocarcinoma cells and tissues. IHC analysis of 49 extrahepatic cholangiocarcinoma patient tumor specimens revealed high expression of GPC1 in 47% of patients. These patients demonstrated significantly poorer prognosis compared with the low-expression group in terms of disease-free survival and overall survival (P < 0.05). GPC1 was also expressed in tumor vessels of cholangiocarcinoma, but not on the vessels of nontumor tissues. MMAF-conjugated GPC1-ADC showed potent tumor growth inhibition against GPC1-positive cholangiocarcinoma cells in vitro and in vivo In a GPC1 knockout xenograft model, GPC1-ADC partially inhibited tumor growth. Vascular endothelial cells in tumor tissues of GPC1-negative xenograft mice expressed GPC1 and were arrested in the G2-M phase of cell cycle by GPC1-ADC. GPC1-ADC exhibits direct as well as indirect antitumor effects via inhibition of tumor angiogenesis. Our preclinical data highlight GPC1-ADC as a promising therapy for GPC1-positive cholangiocarcinoma.
Collapse
Affiliation(s)
- Keiichiro Yokota
- Department of Surgery, Kochi Medical School, Kochi University, Nankoku, Japan.,Department of Clinical Immunology, Kochi Medical School, Kochi University, Nankoku, Japan
| | - Satoshi Serada
- Department of Clinical Immunology, Kochi Medical School, Kochi University, Nankoku, Japan.
| | - Shigehiro Tsujii
- Department of Surgery, Kochi Medical School, Kochi University, Nankoku, Japan.,Department of Clinical Immunology, Kochi Medical School, Kochi University, Nankoku, Japan
| | - Keisuke Toya
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan
| | - Tsuyoshi Takahashi
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan
| | - Takashi Matsunaga
- Department of Medical course, Kochi Medical School, Kochi University, Nankoku, Japan
| | - Minoru Fujimoto
- Department of Clinical Immunology, Kochi Medical School, Kochi University, Nankoku, Japan
| | - Sunao Uemura
- Department of Surgery, Kochi Medical School, Kochi University, Nankoku, Japan
| | - Tsutomu Namikawa
- Department of Surgery, Kochi Medical School, Kochi University, Nankoku, Japan
| | - Ichiro Murakami
- Department of Pathology, Kochi Medical School, Kochi University, Nankoku, Japan
| | - Shogo Kobayashi
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan
| | - Hidetoshi Eguchi
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan
| | - Yuichiro Doki
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan
| | - Kazuhiro Hanazaki
- Department of Surgery, Kochi Medical School, Kochi University, Nankoku, Japan
| | - Tetsuji Naka
- Department of Clinical Immunology, Kochi Medical School, Kochi University, Nankoku, Japan.
| |
Collapse
|
20
|
Yamamoto Y, Hayashi Y, Murakami I. Recurrence of Solitary Fibrous Tumor/Hemangiopericytoma Could Be Predicted by Ki-67 Regardless of Its Origin. Acta Med Okayama 2021; 74:335-343. [PMID: 32843765 DOI: 10.18926/amo/60372] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Since the discovery of the NAB2-STAT6 gene fusion in 2013, solitary fibrous tumor (SFT) and hemangiopericytoma (HPC) have been considered the same disease. STAT6 nuclear stain is approved as a highly sensitive and specific marker to diagnose SFT/HPC from other tumors with similar histology. As the next step, detection of fusion variants that may predict clinical malignancy of SFT/HPC has been attempted. However, no fusion variants with a clear relation to malignancy have been identified. In this study, the clinical and histological backgrounds of 23 Japanese patients diagnosed with SFT/HPC from 2000 to 2019 at Kochi University Hospital were examined to identify factors potentially related to recurrence. A significant relationship to recurrence was detected for mitosis ≥ 1/10 HPF (400×), necrosis, and Ki-67>5%. These findings indicate that a deliberate investigation of histological features such as mitosis and necrosis is crucial for the clinical observation of SFT/ HPC patients. In addition, Ki-67 was revealed to be a useful parameter to predict recurrence in SFT/HPC patients.
Collapse
Affiliation(s)
- Yumiko Yamamoto
- Department of Diagnostic Pathology, Kochi University, Nankoku, Kochi783-8505, Japan.,Department of Ophthalmology, Kochi University, Nankoku, Kochi 783-8505, Japan
| | - Yoshihiro Hayashi
- Department of Equipment of Support Planning Office, Kochi University, Nankoku, Kochi 783-8505, Japan
| | - Ichiro Murakami
- Department of Diagnostic Pathology, Kochi University, Nankoku, Kochi 783-8505, Japan.,Department of Pathology, School of Medicine, Kochi University, Nankoku, Kochi 783-8505, Japan
| |
Collapse
|
21
|
Yoshinuma M, Ida K, Yamasaki K, Chen J, Murakami I. Measurements of radial profile of isotope density ratio using bulk charge exchange spectroscopy. Rev Sci Instrum 2021; 92:063509. [PMID: 34243538 DOI: 10.1063/5.0043607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/09/2021] [Accepted: 05/19/2021] [Indexed: 06/13/2023]
Abstract
A bulk charge exchange spectroscopy (BCXS) system using a grism (grating prism) spectrometer has been applied to measure the profile of the deuterium (D) fraction in deuterium and hydrogen (H) mixture plasma in the Large Helical Device. The observed spectrum can be fitted with four Gaussian functions successfully by reduction of free parameters for the least-squares fit. The plasma flow velocity and ion temperature profile measured by charge exchange spectroscopy using carbon impurity are used for estimation of the wavelength shift of hot components to reduce the free parameter. The ion temperature is used to estimate the apparent wavelength shift due to the energy dependent emission cross section only and is not used to set the Doppler width for H and D in the fitting. The sensitivity of the evaluated D fraction on the velocity is increased for a higher D fraction. The error of the D fraction is calculated from the error in the fitted parameter and sensitivity on the velocity of the hot component. The difference in the profile and time trace of the D fraction with D pellet and H pellet injection was observed clearly by BCXS using a grism spectrometer.
Collapse
Affiliation(s)
- M Yoshinuma
- National Institute for Fusion Science, 322-6 Oroshi-Cho, Toki, Gifu 507-5292, Japan
| | - K Ida
- National Institute for Fusion Science, 322-6 Oroshi-Cho, Toki, Gifu 507-5292, Japan
| | - K Yamasaki
- Graduate School of Advanced Science and Engineering, Hiroshima University, 1-4-1, Kagamiyama, Higashi-Hiroshima City, Hiroshima 739-8527, Japan
| | - J Chen
- School of Nuclear Science and Technology, University of Science and Technology of China, Hefei 230026, China
| | - I Murakami
- National Institute for Fusion Science, 322-6 Oroshi-Cho, Toki, Gifu 507-5292, Japan
| |
Collapse
|
22
|
Sugiura K, Kozuki H, Ueba H, Kubo T, Ochi Y, Baba Y, Miyagawa K, Noguchi T, Hirota T, Yamasaki N, Wada N, Nakashima J, Murakami I, Ikeuchi M, Kitaoka H. Tenosynovial and Cardiac Transthyretin Amyloidosis in Japanese Patients Undergoing Carpal Tunnel Release. Circ Rep 2021; 3:338-344. [PMID: 34136709 PMCID: PMC8180371 DOI: 10.1253/circrep.cr-21-0046] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Background: Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA) is a life-threatening progressive disease. Recent studies have shown that the detection of transthyretin (TTR) amyloid in tenosynovial tissue may play an important role in the diagnosis of cardiac amyloidosis. The aim of this study was to determine the prevalence of TTR amyloid deposits in surgical tissue of patients undergoing carpal tunnel surgery and to clarify the clinical significance of concomitant cardiac examination with 99 mTc-labeled pyrophosphate (99 mTc-PYP) scintigraphy in those patients with TTR deposition. Methods and Results: We evaluated 79 consecutive patients undergoing carpal tunnel release surgery and biopsy of tenosynovial tissue. The mean (±SD) age of the patients at surgery was 71.6±12.5 years (range 30-95 years); 32 patients (41%) were male. TTR amyloid deposition in tenosynovial tissue was observed in 27 patients (34%). Sixteen of those 27 patients underwent 99 mTc-PYP scintigraphy. Of those 16 patients, 3 (19%) had Grade 2 uptake on 99 mTc-PYP scintigraphy. None of the 3 patients with a diagnosis of ATTRwt-CA had apparent cardiac symptoms and left ventricular wall thickness >13 mm. Conclusions: Concomitant cardiac examination with 99 mTc-PYP scintigraphy in patients who had TTR amyloid deposition in tenosynovial tissue resulted in the identification of 19% of patients with a diagnosis of ATTRwt-CA. This diagnostic approach seems to be useful for the early diagnosis of the disease.
Collapse
Affiliation(s)
- Kenta Sugiura
- Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University Nankoku Japan
| | - Hiroki Kozuki
- Department of Orthopedic Surgery, Kochi Medical School, Kochi University Nankoku Japan
| | - Hiroaki Ueba
- Department of Orthopedic Surgery, Kochi Medical School, Kochi University Nankoku Japan
| | - Toru Kubo
- Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University Nankoku Japan
| | - Yuri Ochi
- Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University Nankoku Japan
| | - Yuichi Baba
- Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University Nankoku Japan
| | - Kazuya Miyagawa
- Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University Nankoku Japan
| | - Tatsuya Noguchi
- Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University Nankoku Japan
| | - Takayoshi Hirota
- Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University Nankoku Japan
| | - Naohito Yamasaki
- Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University Nankoku Japan
| | - Noriko Wada
- Department of Pathology, Kochi Medical School, Kochi University Nankoku Japan
| | - Junko Nakashima
- Department of Pathology, Kochi Medical School, Kochi University Nankoku Japan
| | - Ichiro Murakami
- Department of Pathology, Kochi Medical School, Kochi University Nankoku Japan
| | - Masahiko Ikeuchi
- Department of Orthopedic Surgery, Kochi Medical School, Kochi University Nankoku Japan
| | - Hiroaki Kitaoka
- Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University Nankoku Japan
| |
Collapse
|
23
|
Murakami I, Kato D, Oishi T, Goto M, Kawamoto Y, Suzuki C, Sakaue H, Morita S. Progress of tungsten spectral modeling for ITER edge plasma diagnostics based on tungsten spectroscopy in LHD. Nuclear Materials and Energy 2021. [DOI: 10.1016/j.nme.2021.100923] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
24
|
Shigehisa R, Karashima T, Kobayashi S, Atagi K, Takemori D, Fukuhara H, Fukata S, Murakami I, Kuroda N, Inoue K. Synchronous bilateral renal cell carcinomas with differing histologies. IJU Case Rep 2020; 3:196-199. [PMID: 32914073 PMCID: PMC7469849 DOI: 10.1002/iju5.12186] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2020] [Accepted: 06/03/2020] [Indexed: 12/19/2022] Open
Abstract
INTRODUCTION Bilateral renal cell carcinomas with different histological types are rare. We report herein the first description of bilateral renal carcinomas with clear cell renal cell carcinoma and mucinous tubular and spindle cell carcinoma occurring synchronously. CASE PRESENTATION A 62-year-old man was referred to our hospital with bilateral renal tumors. The tumors on each side showed different findings from both contrast-enhanced computed tomography and magnetic resonance imaging. The tumors were partially resected. Histopathological and immunohistochemical examination of the left renal tumor diagnosed clear cell renal carcinoma. Histopathological and immunohistochemical examination of the right renal tumor diagnosed mucinous tubular and spindle cell carcinoma. CONCLUSION We encountered a case with clear cell renal cell carcinoma and mucinous tubular and spindle cell carcinoma occurring simultaneously in bilateral kidneys.
Collapse
Affiliation(s)
- Ryu Shigehisa
- Department of UrologyKochi Medical SchoolNankokuJapan
| | | | - Shu Kobayashi
- Department of UrologyKochi Medical SchoolNankokuJapan
| | - Kaya Atagi
- Department of UrologyKochi Medical SchoolNankokuJapan
| | | | | | | | - Ichiro Murakami
- Laboratory of Diagnostic PathologyKochi Medical School HospitalNankokuJapan
| | - Naoto Kuroda
- Department of Diagnostic PathologyKochi Red Cross HospitalKochiJapan
| | - Keiji Inoue
- Department of UrologyKochi Medical SchoolNankokuJapan
| |
Collapse
|
25
|
Higuchi S, Kawanishi Y, Kondo Y, Nakai E, Fukuda H, Fukui N, Nakajo T, Kobayashi K, Murakami I, Ueba T. [Recurrent High-grade Astroblastoma Treated with Stereotactic Radiotherapy:A Case Report]. No Shinkei Geka 2020; 48:151-158. [PMID: 32094314 DOI: 10.11477/mf.1436204152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
INTRODUCTION Astroblastoma is a rare, supratentorial glial tumor, occurring predominantly in children and young adults. However, treatment strategies have not yet been established for this rare disease. CASE PRESENTATION A 6-year-old boy presented with headache and nausea. CT and MRI revealed a left frontal mass lesion with slight edema and macrocalcifications. Gross tumor resection was performed. Histological examination found neoplastic cells with astroblastic characteristics, and a striking perivascular array of pseudorosettes. The final diagnosis was high-grade astroblastoma. MRI 13 months after surgery suggested local recurrence, and an enlargement was found 3 months later. Stereotactic radiotherapy(SRT)was performed. MRI after SRT showed enhanced cyst formation around the tumor bed, suggesting tumor recurrence. However, <sup>11</sup>C-methionine positron emission tomography(PET)revealed radiation necrosis. The last follow-up MRI 15 months after SRT showed no further recurrence. CONCLUSION Astroblastoma is rare, therefore, no optimal management is known. SRT may be effective to treat recurrent astroblastomas. <sup>11</sup>C-methionine PET/CT was useful to differentiate metastatic disease from radiation necrosis.
Collapse
|
26
|
Hashida Y, Higuchi T, Nakajima K, Ujihara T, Murakami I, Fujieda M, Sano S, Daibata M. Human Polyomavirus 6 with the Asian-Japanese Genotype in Cases of Kimura Disease and Angiolymphoid Hyperplasia with Eosinophilia. J Invest Dermatol 2020; 140:1650-1653.e4. [PMID: 31981580 DOI: 10.1016/j.jid.2019.12.027] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2019] [Revised: 11/06/2019] [Accepted: 12/09/2019] [Indexed: 01/10/2023]
Affiliation(s)
- Yumiko Hashida
- Department of Microbiology and Infection, Kochi Medical School, Kochi University, Kochi, Japan
| | - Tomonori Higuchi
- Department of Microbiology and Infection, Kochi Medical School, Kochi University, Kochi, Japan
| | - Kimiko Nakajima
- Department of Dermatology Kochi Medical School, Kochi University, Kochi, Japan
| | - Takako Ujihara
- Department of Microbiology and Infection, Kochi Medical School, Kochi University, Kochi, Japan; Science Research Center, Kochi Medical School, Kochi University, Kochi, Japan
| | - Ichiro Murakami
- Department of Pathology, Kochi Medical School, Kochi University, Kochi, Japan
| | - Mikiya Fujieda
- Department of Pediatrics, Kochi Medical School, Kochi University, Kochi, Japan
| | - Shigetoshi Sano
- Department of Dermatology Kochi Medical School, Kochi University, Kochi, Japan
| | - Masanori Daibata
- Department of Microbiology and Infection, Kochi Medical School, Kochi University, Kochi, Japan.
| |
Collapse
|
27
|
Fujieda Y, Maeda H, Oba K, Okamoto K, Fukudome I, Shiga M, Kawanishi Y, Akimori T, Kuroiwa H, Nishimoto H, Namikawa T, Murakami I, Kobayashi M, Hanazaki K. Lymph node retrieval after colorectal cancer surgery: a comparative study of the efficacy between the conventional manual method and a new fat dissolution method. Surg Today 2020; 50:726-733. [PMID: 31912338 DOI: 10.1007/s00595-019-01944-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2019] [Accepted: 12/05/2019] [Indexed: 02/08/2023]
Abstract
PURPOSE This study compared the efficacy of two different methods for lymph node (LN) searching after colorectal cancer surgery: the fat dissolution and the conventional manual method. METHODS For the fat dissolution method, we used a commercially available solution of collagenase and lipase (FD group). The primary endpoint was the number of identified LNs in the FD group compared to an historical control (control group) after adjusting by propensity score matching. RESULTS Using 37 matched patients from each group, we identified 20.6 ± 7.2 LNs using the fat dissolution method compared to 13.5 ± 5.9 using the conventional method (t test, P < 0.01). Three patients in the FD group received an inappropriate LN examination in terms of number, while the number of the retrieved LNs was < 12 in 12 patients in the control group. The mean diameter of LNs without metastasis was 3.2 ± 1.9 mm in the FD group, and 40% of metastasis cases were found in LNs < 5 mm in diameter. A pathological examination confirmed that using the fat resolution method did not change the morphological or immunochemical staining findings. CONCLUSION We demonstrated that fat dissolution had a positive impact on the number of retrieved LNs after colorectal cancer surgery without disturbing the microscopic observation.
Collapse
Affiliation(s)
- Yuki Fujieda
- Department of Surgery, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan.,Department of Surgery, Hata-Kenmin Hospital, Sukumo, Kochi, Japan
| | - Hiromichi Maeda
- Department of Surgery, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan.
| | - Koji Oba
- Department of Biostatistics, Graduated School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Ken Okamoto
- Department of Surgery, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan.,Cancer Treatment Center, Kochi Medical School Hospital, Nankoku, Kochi, Japan
| | - Ian Fukudome
- Department of Surgery, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan
| | - Mai Shiga
- Department of Surgery, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan
| | | | - Toyokazu Akimori
- Department of Surgery, Hata-Kenmin Hospital, Sukumo, Kochi, Japan
| | - Hajime Kuroiwa
- Integrated Center for Advanced Medical Technologies (ICAM-Tech), Kochi Medical School, Nankoku, Kochi, Japan
| | - Hiroyuki Nishimoto
- Integrated Center for Advanced Medical Technologies (ICAM-Tech), Kochi Medical School, Nankoku, Kochi, Japan
| | - Tsutomu Namikawa
- Department of Surgery, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan
| | - Ichiro Murakami
- Department of Diagnostic Pathology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan
| | - Michiya Kobayashi
- Department of Surgery, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan.,Cancer Treatment Center, Kochi Medical School Hospital, Nankoku, Kochi, Japan
| | - Kazuhiro Hanazaki
- Department of Surgery, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan
| |
Collapse
|
28
|
Kawai T, Ogata S, Nakashima H, Urabe S, Murakami I, Hiroshima K. Clinicopathologic study of deciduoid mesothelioma using SMARCB1/INI1 immunohistochemistry and fluorescence in situ hybridization. Hum Pathol 2019; 93:23-29. [DOI: 10.1016/j.humpath.2019.08.016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/12/2019] [Revised: 08/14/2019] [Accepted: 08/15/2019] [Indexed: 10/26/2022]
|
29
|
Ida K, Yoshinuma M, Yamasaki K, Kobayashi T, Fujiwara Y, Chen J, Murakami I, Satake S, Yamamoto Y, Murakami S, Kobayashi M. Measurements of radial profile of hydrogen and deuterium density in isotope mixture plasmas using bulk charge exchange spectroscopy. Rev Sci Instrum 2019; 90:093503. [PMID: 31575284 DOI: 10.1063/1.5097030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/22/2019] [Accepted: 08/17/2019] [Indexed: 06/10/2023]
Abstract
A bulk charge exchange spectroscopy system has been applied to measure the radial profiles of the hydrogen (H) and deuterium (D) density ratio in the isotope mixture plasma in a large helical device. Charge exchange lines of Hα and Dα are fitted by 4 Gaussian of H and D cold components and H and D hot components with 5 parameters by combining the measurement of plasma toroidal rotation velocity with carbon charge exchange spectroscopy. The radial profiles of the relative density of hydrogen and deuterium ions are derived from H and D hot components measured and the beam density calculated from beam attenuation calculation. A proof-of-principle experiment is performed by the H pellet and the D pellet injections into the H-D mixture plasma.
Collapse
Affiliation(s)
- K Ida
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Gifu 509-5292, Japan
| | - M Yoshinuma
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Gifu 509-5292, Japan
| | - K Yamasaki
- Research Institute for Applied Mechanics Kyushu University, Kasuga, Fukuoka, Japan
| | - T Kobayashi
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Gifu 509-5292, Japan
| | - Y Fujiwara
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Gifu 509-5292, Japan
| | - J Chen
- School of Nuclear Science and Technology, University of Science and Technology of China, Hefei 230026, China
| | - I Murakami
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Gifu 509-5292, Japan
| | - S Satake
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Gifu 509-5292, Japan
| | - Y Yamamoto
- Department of Nuclear Engineering, Kyoto University, Kyoto 615-8450, Japan
| | - S Murakami
- Department of Nuclear Engineering, Kyoto University, Kyoto 615-8450, Japan
| | - M Kobayashi
- National Institute for Fusion Science, National Institutes of Natural Sciences, Toki, Gifu 509-5292, Japan
| |
Collapse
|
30
|
Yokota K, Serada S, Tsujii S, Hiramatsu K, Namikawa T, Murakami I, Hanazaki K, Naka T. Abstract 4833: Antibody-drug conjugate targeting glypican-1 shows tumor growth inhibition in cholangiocarcinoma. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-4833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Cholangiocarcinoma is one of the most highly malignant cancers. Many patients need systemic chemotherapy for tumor development and recurrence, but their prognosis is poor. Therefore new treatment options are urgently required. We confirmed that the expression of glypican-1 (GPC1) was enhanced in cholangiocarcinoma. GPC1 is a cell surface membrane protein and has been reported as a poor prognostic factor in pancreatic cancer. In this study, we aimed to develop a new therapy for cholangiocarcinoma by the antibody-drug conjugate (ADC) targeting GPC1. By immunohistochemical analysis, enhanced expression of GPC1 was observed in clinical specimens of cholangiocarcinoma. KKU-055 and KKU-100 cells, which are cell lines of cholangiocarcinoma, had high expression of GPC1. In the KKU-055 xenograft model when we administered fluorescently-labeled GPC1 antibody to mice, it accumulated in tumor tissue. We developed a new anti-GPC1 monoclonal antibody (mAb) with highly internalizing activity. The anti-GPC1 mAb was conjugated with the cytotoxic agent monomethyl auristatin F (MMAF). GPC1-ADC showed potent antitumor effect toward KKU-055 and KKU-100 cells compared with the control ADC. In the KKU-055 xenograft model, GPC1-ADC had significant and potent tumor growth inhibition in a dose-dependent manner. In summary, our newly-developed GPC1-ADC showed significant tumor growth inhibition against GPC1-positive cholangiocarcinoma cell lines. Our preclinical data demonstrated that targeting GPC1 by ADC is a promising therapy for GPC1-positive cholangiocarcinoma.
Citation Format: Keiichiro Yokota, Satoshi Serada, Shigehiro Tsujii, Kosuke Hiramatsu, Tsutomu Namikawa, Ichiro Murakami, Kazuhiro Hanazaki, Tetsuji Naka. Antibody-drug conjugate targeting glypican-1 shows tumor growth inhibition in cholangiocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4833.
Collapse
|
31
|
Yorita K, Togashi Y, Nakagawa H, Miyazaki K, Sakata S, Baba S, Takeuchi K, Hayashi Y, Murakami I, Kuroda N, Oda Y, Kohashi K, Yamada Y, Kiyozawa D, Michal M, Michal M. Vocal cord inflammatory myofibroblastic tumor with mucoid deposits harboring TIMP3-ALK fusion: A potential diagnostic pitfall. Pathol Int 2019; 69:366-371. [PMID: 31215130 DOI: 10.1111/pin.12796] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2018] [Revised: 02/25/2019] [Accepted: 02/28/2019] [Indexed: 12/13/2022]
Abstract
A 35-year-old Japanese man who had experienced hoarseness for 10 years presented with a vocal cord lesion. A gross examination revealed a left vocal cord polyp occupying two-thirds of the vocal space. The endoscopically resected lesion contained scattered atypical fibroblastic, stellate, or ganglion-like cells with mucoid stroma. Vacuolated cells were also seen. Lymphoplasmacytic infiltrate was largely undetectable. A vocal cord polyp was first suspected, but well-differentiated liposarcoma and inflammatory myofibroblastic tumor (IMT) were included in the differential diagnoses. The tumor cells were positive for anaplastic lymphoma kinase (ALK), calponin, and vimentin, and negative for other smooth muscle markers by immunohistochemistry. Structures resembling myofibroblasts were not observed by electron microscopy, which confirmed abundant rough endoplasmic reticulum in the tumor cells and accumulated lipid droplets in some tumor cells. ALK gene rearrangement was detected by fluorescence in situ hybridization, and TIMP3-ALK fusion was confirmed by 5' rapid amplification of cDNA ends. We diagnosed the lesion as an IMT, and an ALK-rearranged stellate cell tumor may be postulated. This is the first report of a fusion partner gene of ALK in a case of laryngeal IMT.
Collapse
Affiliation(s)
- Kenji Yorita
- Department of Diagnostic Pathology, Japanese Red Cross Kochi Hospital, Kochi, Japan
| | - Yuki Togashi
- Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.,Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
| | - Hideyuki Nakagawa
- Department of Otorhinolaryngology, Japanese Red Cross Kochi Hospital, Kochi, Japan
| | - Katsushi Miyazaki
- Department of Otorhinolaryngology, Japanese Red Cross Kochi Hospital, Kochi, Japan
| | - Seiji Sakata
- Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
| | - Satoko Baba
- Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.,Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
| | - Kengo Takeuchi
- Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.,Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
| | - Yoshihiro Hayashi
- Equipment of Support Planning Office, Kochi University, Kochi, Japan
| | - Ichiro Murakami
- Department of Pathology, Kochi Medical School, Kochi University, Kochi, Japan
| | - Naoto Kuroda
- Department of Diagnostic Pathology, Japanese Red Cross Kochi Hospital, Kochi, Japan
| | - Yoshinao Oda
- Department of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Kenichi Kohashi
- Department of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Yuichi Yamada
- Department of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Daisuke Kiyozawa
- Department of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Michael Michal
- Department of Pathology, Charles University, Medical Faculty and Charles University Hospital Plzen, Pilsen, Czech Republic
| | - Michal Michal
- Department of Pathology, Charles University, Medical Faculty and Charles University Hospital Plzen, Pilsen, Czech Republic
| |
Collapse
|
32
|
Suzuki C, Mukai K, Masuzaki S, Kobayashi M, Peterson B, Akiyama T, Murakami I. Spectroscopic studies on the enhanced radiation with high Z rare gas seeding for mitigating divertor heat loads in LHD plasmas. Nuclear Materials and Energy 2019. [DOI: 10.1016/j.nme.2019.02.039] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
33
|
Namikawa T, Tsuda S, Fujisawa K, Munekage E, Iwabu J, Munekage M, Uemura S, Tsujii S, Maeda H, Kitagawa H, Iguchi M, Murakami I, Kobayashi M, Hanazaki K. Intrahepatic bile duct adenoma in a patient with gastric cancer. Int Cancer Conf J 2019; 8:7-11. [PMID: 31149539 PMCID: PMC6498292 DOI: 10.1007/s13691-018-0345-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2018] [Accepted: 09/10/2018] [Indexed: 12/14/2022] Open
Abstract
We report a case of intrahepatic bile duct adenoma (BDA) detected during laparoscopic distal gastrectomy for gastric cancer. A 70-year-old man was referred to our hospital for the treatment of gastric cancer. Esophagogastroduodenoscopy revealed an irregular, nodular, and elevated lesion on the greater curvature side of the middle third of the stomach. Abdominal contrast-enhanced computed tomography showed wall thickening with homogeneous enhancement in the middle part of the stomach, and no lesions in the liver. The patient underwent laparoscopic distal gastrectomy with regional lymphadenectomy, and during the operation a small whitish nodule was observed on the lateral segment of the liver surface. The lesion was excised by partial resection of the liver for the purpose of both histological diagnosis and treatment. Pathological examination of the liver lesion revealed no structural or cellular atypia, no stromal invasion, and immunohistochemical positivity for CK7 and CK19, but negativity for p53. The final diagnosis was well-differentiated adenocarcinoma invading the gastric serosal layer without lymph node metastasis, and intrahepatic BDA measuring 0.4 × 0.3 cm. Following surgery, the patient remained symptom-free without evidence of recurrence for 5 months. To the best of our knowledge, this is the first case of BDA with gastric cancer. Because it is difficult to distinguish BDA from other liver tumors including metastatic cancer due to its characteristically small size and lack of specific morphological features on standard imaging, surgical resection should be considered as the most suitable approach for both accurate diagnosis and treatment.
Collapse
Affiliation(s)
- Tsutomu Namikawa
- Department of Surgery, Kochi Medical School, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505 Japan
| | - Sachi Tsuda
- Department of Surgery, Kochi Medical School, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505 Japan
| | - Kazune Fujisawa
- Department of Surgery, Kochi Medical School, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505 Japan
| | - Eri Munekage
- Department of Surgery, Kochi Medical School, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505 Japan
| | - Jun Iwabu
- Department of Surgery, Kochi Medical School, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505 Japan
| | - Masaya Munekage
- Department of Surgery, Kochi Medical School, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505 Japan
| | - Sunao Uemura
- Department of Surgery, Kochi Medical School, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505 Japan
| | - Shigehiro Tsujii
- Department of Surgery, Kochi Medical School, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505 Japan
| | - Hiromichi Maeda
- Cancer Treatment Center, Kochi Medical School Hospital, Kochi, Japan
| | - Hiroyuki Kitagawa
- Department of Surgery, Kochi Medical School, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505 Japan
| | - Mitsuko Iguchi
- Department of Pathology, Kochi Medical School, Kochi, Japan
| | | | - Michiya Kobayashi
- Cancer Treatment Center, Kochi Medical School Hospital, Kochi, Japan
- Department of Human Health and Medical Sciences, Kochi Medical School, Kochi, Japan
| | - Kazuhiro Hanazaki
- Department of Surgery, Kochi Medical School, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505 Japan
| |
Collapse
|
34
|
Suda K, Kim J, Murakami I, Rozeboom L, Rivard C, Mitsudomi T, Tan A, Hirsch F. P2.04-15 Heterogeneity and Correlation Between Immune Markers in Lung Cancers: Analysis of Treatment-Naïve Lesions. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
35
|
Kikuchi H, Higuchi T, Hashida Y, Taniguchi A, Kamioka M, Taguchi T, Yokoyama A, Murakami I, Fujieda M, Daibata M. Generation and characteristics of a novel "double-hit" high grade B-cell lymphoma cell line DH-My6 with MYC/ IGH and BCL6/ IGH gene arrangements and potential molecular targeted therapies. Oncotarget 2018; 9:33482-33499. [PMID: 30323893 PMCID: PMC6173362 DOI: 10.18632/oncotarget.26060] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2018] [Accepted: 08/10/2018] [Indexed: 12/04/2022] Open
Abstract
“Double-hit” lymphoma (DHL) is a high-grade B-cell lymphoma that harbors concurrent MYC and BCL2 or BCL6 rearrangements. Because cases of MYC/BCL6 DHL are uncommon, most reported conclusions have been based on cases of MYC/BCL2 DHL. Lack of experimental MYC/BCL6 DHL models continues to hinder the pathophysiologic and therapeutic investigations of this disorder. We herein describe a novel MYC/BCL6 DHL cell line, designated DH-My6, carrying both the MYC–IGH and BCL6–IGH fusion genes. Interruptions of MYC and BCL6 expressions using short interfering RNAs and chemical inhibitors led to significant attenuation of DH-My6 cell growth. Greater antitumor effects were found when the cells were treated with a combination of MYC and BCL6 inhibitors. Moreover, the PLK1 inhibitor volasertib and the HDAC inhibitor vorinostat synergized strongly when combined with the bromodomain inhibitor JQ1. DH-My6 is a new well-validated MYC/BCL6 DHL cell line that will provide a useful model for studies of the pathogenesis and therapeutics for the less common DHL tumor type. The rationale for approaches targeting both MYC and BCL6, and in combination with PLK1 or HDAC inhibitors for superior suppression of the aggressive MYC/BCL6 DHL warrants further in vivo testing in a preclinical model.
Collapse
Affiliation(s)
- Hiroaki Kikuchi
- Department of Microbiology and Infection, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan.,Department of Pediatrics, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan
| | - Tomonori Higuchi
- Department of Microbiology and Infection, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan
| | - Yumiko Hashida
- Department of Microbiology and Infection, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan
| | - Ayuko Taniguchi
- Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan
| | - Mikio Kamioka
- Department of Laboratory Medicine, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan
| | - Takahiro Taguchi
- Department of Molecular and Cellular Biology, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan
| | - Akihito Yokoyama
- Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan
| | - Ichiro Murakami
- Department of Pathology, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan
| | - Mikiya Fujieda
- Department of Pediatrics, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan
| | - Masanori Daibata
- Department of Microbiology and Infection, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan
| |
Collapse
|
36
|
Murakami I, Wada N, Nakashima J, Iguchi M, Toi M, Hashida Y, Higuchi T, Daibata M, Matsushita M, Iwasaki T, Kuwamoto S, Horie Y, Nagata K, Hayashi K, Oka T, Yoshino T, Imamura T, Morimoto A, Imashuku S, Gogusev J, Jaubert F. Merkel cell polyomavirus and Langerhans cell neoplasm. Cell Commun Signal 2018; 16:49. [PMID: 30134914 PMCID: PMC6103986 DOI: 10.1186/s12964-018-0261-y] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2018] [Accepted: 08/14/2018] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND The relationship between various external agents such as pollen, food, and infectious agents and human sensitivity exists and is variable depending upon individual's health conditions. For example, we believe that the pathogenetic potential of the Merkel cell polyomavirus (MCPyV), the resident virus in skin, is variable and depends from the degree of individual's reactivity. MCPyV as well as Epstein-Barr virus, which are normally connected with humans under the form of subclinical infection, are thought to be involved at various degrees in several neoplastic and inflammatory diseases. In this review, we cover two types of Langerhans cell neoplasms, the Langerhans cell sarcoma (LCS) and Langerhans cell histiocytosis (LCH), represented as either neoplastic or inflammatory diseases caused by MCPyV. METHODS We meta-analyzed both our previous analyses, composed of quantitative PCR for MCPyV-DNA, proteomics, immunohistochemistry which construct IL-17 endocrine model and interleukin-1 (IL-1) activation loop model, and other groups' data. RESULTS We have shown that there were subgroups associated with the MCPyV as a causal agent in these two different neoplasms. Comparatively, LCS, distinct from the LCH, is a neoplastic lesion (or sarcoma) without presence of inflammatory granuloma frequently observed in the elderly. LCH is a proliferative disease of Langerhans-like abnormal cells which carry mutations of genes involved in the RAS/MAPK signaling pathway. We found that MCPyV may be involved in the development of LCH. CONCLUSION We hypothesized that a subgroup of LCS developed according the same mechanism involved in Merkel cell carcinoma pathogenesis. We proposed LCH developed from an inflammatory process that was sustained due to gene mutations. We hypothesized that MCPyV infection triggered an IL-1 activation loop that lies beneath the pathogenesis of LCH and propose a new triple-factor model.
Collapse
Affiliation(s)
- Ichiro Murakami
- Department of Pathology, Kochi Medical School, Kochi University, Kohasu, Okoh, Nankoku, Kochi 783-8505 Japan
- Department of Pathology, Kochi University Hospital, 185-1 Kohasu, Okoh, Nankoku, Kochi 783-8505 Japan
| | - Noriko Wada
- Department of Pathology, Kochi University Hospital, 185-1 Kohasu, Okoh, Nankoku, Kochi 783-8505 Japan
| | - Junko Nakashima
- Department of Pathology, Kochi Medical School, Kochi University, Kohasu, Okoh, Nankoku, Kochi 783-8505 Japan
- Department of Pathology, Kochi University Hospital, 185-1 Kohasu, Okoh, Nankoku, Kochi 783-8505 Japan
| | - Mitsuko Iguchi
- Department of Pathology, Kochi Medical School, Kochi University, Kohasu, Okoh, Nankoku, Kochi 783-8505 Japan
- Department of Pathology, Kochi University Hospital, 185-1 Kohasu, Okoh, Nankoku, Kochi 783-8505 Japan
| | - Makoto Toi
- Department of Pathology, Kochi University Hospital, 185-1 Kohasu, Okoh, Nankoku, Kochi 783-8505 Japan
| | - Yumiko Hashida
- Department of Microbiology and Infection, Kochi Medical School, Kochi University, Kohasu, Okoh, Nankoku, Kochi 783-8505 Japan
| | - Tomonori Higuchi
- Department of Microbiology and Infection, Kochi Medical School, Kochi University, Kohasu, Okoh, Nankoku, Kochi 783-8505 Japan
| | - Masanori Daibata
- Department of Microbiology and Infection, Kochi Medical School, Kochi University, Kohasu, Okoh, Nankoku, Kochi 783-8505 Japan
| | - Michiko Matsushita
- Department of Pathobiological Science and Technology, School of Health Science, Faculty of Medicine, Tottori University, 86 Nishi, Yonago, Tottori, 683-8503 Japan
| | - Takeshi Iwasaki
- Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, Fukuoka 812-8582 Japan
| | - Satoshi Kuwamoto
- Department of Pathology, Tottori University Hospital, 86 Nishi, Yonago, Tottori, 683-8503 Japan
- Division of Molecular Pathology, Faculty of Medicine, Tottori University, 86 Nishi, Yonago, Tottori, 683-8503 Japan
| | - Yasushi Horie
- Department of Pathology, Tottori University Hospital, 86 Nishi, Yonago, Tottori, 683-8503 Japan
| | - Keiko Nagata
- Division of Molecular Pathology, Faculty of Medicine, Tottori University, 86 Nishi, Yonago, Tottori, 683-8503 Japan
| | - Kazuhiko Hayashi
- Division of Molecular Pathology, Faculty of Medicine, Tottori University, 86 Nishi, Yonago, Tottori, 683-8503 Japan
| | - Takashi Oka
- Department of Virology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata, Kita-ku, Okayama, Okayama 700-8558 Japan
| | - Tadashi Yoshino
- Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata, Kita-ku, Okayama, Okayama 700-8558 Japan
| | - Toshihiko Imamura
- Department of Pediatrics, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, 465 Kajii, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, Kyoto 602-8566 Japan
| | - Akira Morimoto
- Department of Pediatrics, Jichi Medical University School of Medicine, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498 Japan
| | - Shinsaku Imashuku
- Division of Laboratory Medicine, Uji-Tokushukai Medical Center, 145 Ishibashi, Makishima, Uji, Kyoto, 611-0041 Japan
| | - Jean Gogusev
- Inserm U507 and U1016, Institut Cochin, 75014 Paris, France
| | - Francis Jaubert
- AP-HP Hôpital Necker-Enfants Malades, University Paris Descartes (Paris 5), 75006 Paris, France
| |
Collapse
|
37
|
Takei Y, Ueshima C, Kataoka TR, Hirata M, Sugimoto A, Rokutan-Kurata M, Moriyoshi K, Ono K, Murakami I, Iwamoto S, Haga H. Killer cell immunoglobulin-like receptor 2DL4 is expressed in and suppresses the cell growth of Langerhans cell histiocytosis. Oncotarget 2018; 8:36964-36972. [PMID: 28445138 PMCID: PMC5514884 DOI: 10.18632/oncotarget.16936] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2016] [Accepted: 03/26/2017] [Indexed: 11/30/2022] Open
Abstract
Killer cell immunoglobulin-like receptor (KIR) 2DL4 (CD158d) is a receptor for human leukocyte antigen-G. The function of KIR2DL4 has been reported in human natural killer cell lymphoma and mastocytosis, but not in Langerhans cell histiocytosis (LCH). Herein, we examined the expression and function of KIR2DL4 in LCHs. In pathological specimens, 27 of 36 LCH cases (75.0%) were immunohistochemically positive for KIR2DL4. Its expression was independent of age, gender, location, multi- or single-system, and the status of BRAFV600E immunostaining. We also confirmed the expression of KIR2DL4 mRNA and protein in the human LCH-like cell lines ELD-1 and PRU-1. KIR2DL4 protein was distributed in the membrane and cytoplasm of ELD-1 cells, but only in the cytoplasm of PRU-1 cells. An agonistic antibody against KIR2DL4 reduced phosphorylation of extracellular signal-regulated kinases (ERKs) and suppressed the cell growth of ELD-1 cells in a Src homology region 2 domain-containing phosphatase-2 dependent manner, but it had no effect in PRU-1 cells. These results suggest that KIR2DL4-mediated ERK suppression is a possible therapeutic target for LCH cells.
Collapse
Affiliation(s)
- Yusuke Takei
- Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan
| | - Chiyuki Ueshima
- Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan
| | - Tatsuki R Kataoka
- Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan
| | - Masahiro Hirata
- Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan
| | - Akihiko Sugimoto
- Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan
| | | | - Koki Moriyoshi
- Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.,Department of Diagnostic Pathology, Kyoto Medical Center, Kyoto, Japan
| | - Kazuo Ono
- Department of Pathology, Japan Red Cross Society Wakayama Medical Center, Wakayama, Japan
| | - Ichiro Murakami
- Department of Pathology, School of Medicine, Kochi University Faculty of Medicine, Nankoku, Kochi, Japan
| | - Sanju Iwamoto
- Department of Pharmacology, Toxicology & Therapeutics, Division of Physiology & Pathology, Showa University School of Pharmacy, Tokyo, Japan
| | - Hironori Haga
- Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan
| |
Collapse
|
38
|
Yorita K, Yoshii S, Kuroda N, Senzaki Y, Nakagawa K, Iwata J, Hirose T, Murakami I. A case of desmoplastic melanoma that was difficult to distinguish from malignant peripheral nerve sheath tumor. Human Pathology: Case Reports 2018. [DOI: 10.1016/j.ehpc.2017.08.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
|
39
|
Ohtsuki Y, Ozawa A, Iseda T, Kurabayashi A, Murakami I, Furihata M. Immunohistochemical analyses in a case of high grade urothelial carcinoma featuring rare chordoid features. Biomed Res 2018. [DOI: 10.4066/biomedicalresearch.29-18-961] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
40
|
Maeda H, Okamoto K, Oba K, Shiga M, Fujieda Y, Namikawa T, Hiroi M, Murakami I, Hanazaki K, Kobayashi M. Lymph node retrieval after dissolution of surrounding adipose tissue for pathological examination of colorectal cancer. Oncol Lett 2017; 15:2495-2500. [PMID: 29434964 DOI: 10.3892/ol.2017.7629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2017] [Accepted: 11/24/2017] [Indexed: 02/05/2023] Open
Abstract
Examination of >12 lymph nodes (LNs) is important for the diagnostic accuracy of nodal status following resection of colorectal cancer. In the present study, the efficacy of a fat dissolution technique for LN retrieval was evaluated using resected colon and rectum mesentery. First, the resected mesentery was searched for LNs by inspection and palpation immediately after surgery. Subsequently, fat dissolution liquid was applied to the remnant fat and the LN search was repeated. The primary endpoint was whether the second assessment would increase the number of evaluated LNs. Recruitment of 20 patients was planned. The study was conducted after institutional review board approval and written informed consent was obtained. Among 20 participants, 1 patient was excluded because LN dissection was not performed. The median number of LNs identified at the first and second assessments was 13 and 6, respectively, producing a significant increase in total LNs evaluated (13 vs. 20, respectively; P<0.01; paired t-test). One positive node was identified among the additionally identified LNs (0.9%, 1/107). The second assessment increased the number of LNs assessed to >12 in 4 patients, and although staging was not changed, the treatment was potentially altered in 2 stage II patients. The maximum diameter of the additionally obtained LNs was significantly smaller compared with those from the first assessment (4 vs. 7.7 mm, respectively; P<0.01; Wilcoxon signed-rank test). After the fat dissolution technique, the tumor cells were satisfactorily stained by carcinoembryonic antigen and cytokeratin-20. In conclusion, applying fat dissolution liquid to the remnant adipose tissue of the mesentery of the colon and rectum identified additional LNs. This method should be considered when insufficient LNs are identified after conventional LN retrieval.
Collapse
Affiliation(s)
- Hiromichi Maeda
- Cancer Treatment Center, Kochi Medical School Hospital, Kochi 783-8505, Japan
| | - Ken Okamoto
- Cancer Treatment Center, Kochi Medical School Hospital, Kochi 783-8505, Japan
| | - Koji Oba
- Department of Biostatistics, Graduated School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan
| | - Mai Shiga
- Depatment of Surgery, Kochi Medical School, Kochi University, Kochi 783-8505, Japan
| | - Yuki Fujieda
- Depatment of Surgery, Kochi Medical School, Kochi University, Kochi 783-8505, Japan
| | - Tsutomu Namikawa
- Depatment of Surgery, Kochi Medical School, Kochi University, Kochi 783-8505, Japan
| | - Makoto Hiroi
- Department of Diagnostic Pathology, Kochi Medical School, Kochi University, Kochi 783-8505, Japan
| | - Ichiro Murakami
- Department of Diagnostic Pathology, Kochi Medical School, Kochi University, Kochi 783-8505, Japan
| | - Kazuhiro Hanazaki
- Depatment of Surgery, Kochi Medical School, Kochi University, Kochi 783-8505, Japan
| | - Michiya Kobayashi
- Cancer Treatment Center, Kochi Medical School Hospital, Kochi 783-8505, Japan
| |
Collapse
|
41
|
Suda K, Murakami I, Yu H, Kim J, Mizuuchi H, Ellison K, Rivard C, Tan A, Mitsudomi T, Hirsch F. PS06.01 CD44 Confers EMT Phenotypic Change Following Resistance to EGFR-TKIs in Lung Cancer. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
42
|
Suda K, Kim J, Murakami I, Rozeboom L, Rivard C, Mitsudomi T, Tan A, Hirsch F. OA 07.06 Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
43
|
Machihara K, Tanaka H, Hayashi Y, Murakami I, Namba T. Questiomycin A stimulates sorafenib-induced cell death via suppression of glucose-regulated protein 78. Biochem Biophys Res Commun 2017; 492:33-40. [PMID: 28811106 DOI: 10.1016/j.bbrc.2017.08.042] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2017] [Accepted: 08/12/2017] [Indexed: 12/25/2022]
Abstract
Hepatocellular carcinoma (HCC) is one of the most difficult cancers to treat owing to the lack of effective chemotherapeutic methods. Sorafenib, the first-line and only available treatment for HCC, extends patient overall survival by several months, with a response rate below 10%. Thus, the identification of an agent that enhances the anticancer effect of sorafenib is critical for the development of therapeutic options for HCC. Endoplasmic reticulum (ER) stress response is one of the methods of sorafenib-induced cell death. Here we report that questiomycin A suppresses expression of GRP78, a cell-protective ER chaperone protein. Analysis of the molecular mechanisms of questiomycin A revealed that this compound stimulated GRP78 protein degradation in an ER stress response-independent manner. Cotreatment with sorafenib and questiomycin A suppressed GRP78 protein expression, which is essential for the stimulation of sorafenib-induced cell death. Moreover, our in vivo study demonstrated that the coadministration of sorafenib and questiomycin A suppressed tumor formation in HCC-induced xenograft models. These results suggest that cotreatment with sorafenib and questiomycin A is a novel therapeutic strategy for HCC by enhancing sorafenib-dependent ER stress-induced cell death, and downregulation of GRP78 is a new target for the stimulation of the therapeutic effects of sorafenib in HCC.
Collapse
Affiliation(s)
- Kayo Machihara
- Science Research Center, Kochi University, Kochi 783-8505, Japan
| | - Hidenori Tanaka
- Science Research Center, Kochi University, Kochi 783-8505, Japan
| | - Yoshihiro Hayashi
- Equipment of Support Planning Office, Kochi University, Kochi 783-8505, Japan
| | - Ichiro Murakami
- Department of Pathology, Kochi Medical School, Kochi University, Kochi 783-8505, Japan
| | - Takushi Namba
- Science Research Center, Kochi University, Kochi 783-8505, Japan.
| |
Collapse
|
44
|
Kobayashi T, Yoshikawa M, Kato T, Murakami I, Kubota Y, Matama K, Cho T. Study of Oxygen Ions Behavior by Using Collisional-Radiative Model in GAMMA 10. Fusion Science and Technology 2017. [DOI: 10.13182/fst07-a1367] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- T. Kobayashi
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - M. Yoshikawa
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - T. Kato
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - I. Murakami
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - Y. Kubota
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - K. Matama
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| | - T. Cho
- Plasma Research Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan
| |
Collapse
|
45
|
Murakami I, Kato D, Kato M, Sakaue HA, Kato T. NIFS Atomic and Molecular Database for Collision Processes in Plasma. Fusion Science and Technology 2017. [DOI: 10.13182/fst07-a1334] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- I. Murakami
- Atomic and Molecular Data Research Center, Coordinate Research Center, National Institute for Fusion Science, Toki, Gifu, 509-5292, Japan
| | - D. Kato
- Atomic and Molecular Data Research Center, Coordinate Research Center, National Institute for Fusion Science, Toki, Gifu, 509-5292, Japan
| | - M. Kato
- Atomic and Molecular Data Research Center, Coordinate Research Center, National Institute for Fusion Science, Toki, Gifu, 509-5292, Japan
| | - H. A. Sakaue
- Atomic and Molecular Data Research Center, Coordinate Research Center, National Institute for Fusion Science, Toki, Gifu, 509-5292, Japan
| | - T. Kato
- Atomic and Molecular Data Research Center, Coordinate Research Center, National Institute for Fusion Science, Toki, Gifu, 509-5292, Japan
| |
Collapse
|
46
|
Motojima O, Yamada H, Komori A, Watanabe KY, Mutoh T, Takeiri Y, Ida K, Akiyama T, Asakura N, Ashikawa N, Chikaraishi H, Cooper WA, Emoto M, Fujita T, Fujiwara M, Funaba H, Goncharov P, Goto M, Hamada Y, Higashijima S, Hino T, Hoshino M, Ichimura M, Idei H, Ido T, Ikeda K, Imagawa S, Inagaki S, Isayama A, Isobe M, Itoh T, Itoh K, Kado S, Kalinina D, Kaneba T, Kaneko O, Kato D, Kato T, Kawahata K, Kawashima H, Kawazome H, Kobuchi T, Kondo K, Kubo S, Kumazawa R, Lyon JF, Maekawa R, Mase A, Masuzaki S, Mito T, Matsuoka K, Miura Y, Miyazawa J, More R, Morisaki T, Morita S, Murakami I, Murakami S, Mutoh S, Nagaoka K, Nagasaki K, Nagayama Y, Nakamura Y, Nakanishi H, Narihara K, Narushima Y, Nishimura H, Nishimura K, Nishiura M, Nishizawa A, Noda N, Notake T, Nozato H, Ohdachi S, Ohkubo K, Ohyabu N, Oyama N, Oka Y, Okada H, Osakabe M, Ozaki T, Peterson BJ, Sagara A, Saida T, Saito K, Sakakibara S, Sakamoto M, Sakamoto R, Sasao M, Sato K, Seki T, Shimozuma T, Shoji M, Sudo S, Takagi S, Takahashi Y, Takase Y, Takenaga H, Takeuchi N, Tamura N, Tanaka K, Tanaka M, Toi K, Takahata K, Tokuzawa T, Torii Y, Tsumori K, Watanabe F, Watanabe M, Watanabe T, Watari T, Yamada I, Yamada S, Yamaguchi T, Yamamoto S, Yamazaki K, Yanagi N, Yokoyama M, Yoshida N, Yoshimura S, Yoshimura Y, Yoshinuma M. Review on the Progress of the LHD Experiment. Fusion Science and Technology 2017. [DOI: 10.13182/fst04-a535] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- O. Motojima
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Yamada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Komori
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Y. Watanabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Mutoh
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Takeiri
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Ida
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Akiyama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Asakura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Ashikawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Chikaraishi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - W. A. Cooper
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Emoto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Fujita
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Fujiwara
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Funaba
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - P. Goncharov
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Goto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Hamada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Higashijima
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Hino
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Hoshino
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Ichimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Idei
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Ido
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Ikeda
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Imagawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Inagaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Isayama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Isobe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Itoh
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Itoh
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Kado
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - D. Kalinina
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Kaneba
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - O. Kaneko
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - D. Kato
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Kato
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Kawahata
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Kawashima
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Kawazome
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Kobuchi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Kondo
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Kubo
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - R. Kumazawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - J. F. Lyon
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - R. Maekawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Mase
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Masuzaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Mito
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Matsuoka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Miura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - J. Miyazawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - R. More
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Morisaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Morita
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - I. Murakami
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Murakami
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Mutoh
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Nagaoka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Nagasaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Nagayama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Nakamura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Nakanishi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Narihara
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Narushima
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Nishimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Nishimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Nishiura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Nishizawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Noda
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Notake
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Nozato
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Ohdachi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Ohkubo
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Ohyabu
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Oyama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Oka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Okada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Osakabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Ozaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - B. J. Peterson
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - A. Sagara
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Saida
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Saito
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Sakakibara
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Sakamoto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - R. Sakamoto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Sasao
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Sato
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Seki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Shimozuma
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Shoji
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Sudo
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Takagi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Takahashi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Takase
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - H. Takenaga
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Takeuchi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Tamura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Tanaka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Tanaka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Toi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Takahata
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Tokuzawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Torii
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Tsumori
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - F. Watanabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Watanabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Watanabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Watari
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - I. Yamada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Yamada
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - T. Yamaguchi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Yamamoto
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - K. Yamazaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Yanagi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Yokoyama
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - N. Yoshida
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - S. Yoshimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - Y. Yoshimura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| | - M. Yoshinuma
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki-shi, Gifu-ken 509-5292, Japan
| |
Collapse
|
47
|
Mohri T, Nagata K, Kuwamoto S, Matsushita M, Sugihara H, Kato M, Horie Y, Murakami I, Hayashi K. Aberrant expression of AID and AID activators of NF-κB and PAX5 is irrelevant to EBV-associated gastric cancers, but is associated with carcinogenesis in certain EBV-non-associated gastric cancers. Oncol Lett 2017; 13:4133-4140. [PMID: 28588701 PMCID: PMC5452920 DOI: 10.3892/ol.2017.5978] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2016] [Accepted: 02/13/2017] [Indexed: 12/13/2022] Open
Abstract
Epstein-Barr virus-associated gastric carcinoma (EBVaGC) is a distinct subtype of gastric cancer characterized by clinicopathological features including lymphoepithelioma-like histology. Aberrant expression of activation-induced cytidine deaminase (AID) as a genomic modulator was demonstrated through pathogen-related nuclear factor κB (NF-κB) signaling in Helicobacter pylori-associated gastric cancer. To elucidate whether or not AID expression is relevant to carcinogenesis in EBVaGC, immunohistochemical expression of AID and AID-regulatory factors between EBVaGC and EBV-non-associated gastric carcinoma (GC) were evaluated, each using 15 cases of GC with lymphoid stroma (GCLS) and other types of GC. Aberrant expression of AID, NF-κB and paired box 5 (PAX5) were significantly decreased in EBVaGC (0/11, 1/11 and 1/11) compared with in EBV-non-associated GC (7/19, 12/19 and 11/19) (P=0.025, 0.005 and 0.01, respectively); however, no significant difference in c-Myb proto-oncogene expression was identified. AID expression was also decreased in EBV-associated GCLS (0/10) compared with in EBV-non-associated GCLS (3/5). Unexpectedly, decreased expression of NF-κB and PAX5 was observed in GCLS (1/15 and 2/15) compared with in GC without LS (12/15 and 10/15) (P<0.001 and P=0.003, respectively). Decreased AID expression observed in EBVaGC is consistent with the reported molecular characterization of hypermethylation and rare somatic gene mutation in EBVaGC. Only PAX5 was identified to be significantly associated with venous invasion (P=0.022). The results of the present study suggest that pathogen-induced AID expression may be irrelevant to carcinogenesis of EBVaGC, whereas it contributes to carcinogenesis in certain types of EBV-non-associated GC.
Collapse
Affiliation(s)
- Takashi Mohri
- Division of Molecular Pathology, Department of Pathology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan
| | - Keiko Nagata
- Division of Molecular Pathology, Department of Pathology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan
| | - Satoshi Kuwamoto
- Division of Molecular Pathology, Department of Pathology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan.,Department of Diagnostic Pathology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan
| | - Michiko Matsushita
- Department of Pathobiological Science and Technology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan
| | - Hirotsugu Sugihara
- Division of Molecular Pathology, Department of Pathology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan
| | - Masako Kato
- Division of Molecular Pathology, Department of Pathology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan
| | - Yasushi Horie
- Department of Diagnostic Pathology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan
| | - Ichiro Murakami
- Department of Pathology, Faculty of Medicine, Kochi Medical School, Nankoku, Kochi 783-8505, Japan
| | - Kazuhiko Hayashi
- Division of Molecular Pathology, Department of Pathology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan
| |
Collapse
|
48
|
Nagata K, Kumata K, Nakayama Y, Satoh Y, Sugihara H, Hara S, Matsushita M, Kuwamoto S, Kato M, Murakami I, Hayashi K. Epstein-Barr Virus Lytic Reactivation Activates B Cells Polyclonally and Induces Activation-Induced Cytidine Deaminase Expression: A Mechanism Underlying Autoimmunity and Its Contribution to Graves' Disease. Viral Immunol 2017; 30:240-249. [PMID: 28333576 PMCID: PMC5393416 DOI: 10.1089/vim.2016.0179] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Graves' disease is an autoimmune disease that results in and is the most common cause of hyperthyroidism, and the reactivation of persisting Epstein–Barr virus (EBV) in B lymphocytes induces the differentiation of host B cells into plasma cells. We previously reported that some EBV-infected B cells had thyrotropin receptor antibodies (TRAbs) as surface immunoglobulins (Igs), and EBV reactivation induced these TRAb+EBV+ cells to produce TRAbs. EBV reactivation induces Ig production from host B cells. The purpose of the present study was to examine total Ig productions from B cell culture fluids and to detect activation-induced cytidine deaminase (AID), nuclear factor kappa B (NF-κB), and EBV latent membrane protein (LMP) 1 in culture B cells during EBV reactivation induction and then we discussed the mechanisms of EBV reactivation-induced Ig production in relation to autoimmunity. We showed that the EBV reactivation induces the production of every isotype of Ig and suggested that the Ig production was catalyzed by AID through LMP1 and NF-κB. The results that the amount of IgM was significantly larger compared with IgG suggested the polyclonal B cell activation due to LMP1. We proposed the pathway of EBV reactivation induced Ig production; B cells newly infected with EBV are activated by polyclonal B cell activation and produce Igs through plasma cell differentiation induced by EBV reactivation. LMP1-induced AID enabled B cells to undergo class-switch recombination to produce every isotype of Ig. According to this mechanism, EBV rescues autoreactive B cells to produce autoantibodies, which contribute to the development and exacerbation of autoimmune diseases.
Collapse
Affiliation(s)
- Keiko Nagata
- 1 Division of Molecular Pathology, Department of Pathology, Faculty of Medicine, Tottori University , Yonago, Japan
| | - Keisuke Kumata
- 1 Division of Molecular Pathology, Department of Pathology, Faculty of Medicine, Tottori University , Yonago, Japan
| | - Yuji Nakayama
- 2 Division of Functional Genomics, Research Center for Bioscience and Technology, Tottori University , Yonago, Japan
| | - Yukio Satoh
- 3 Division of Biosignaling, Department of Biomedical Sciences, Faculty of Medicine, Tottori University , Yonago, Japan
| | - Hirotsugu Sugihara
- 1 Division of Molecular Pathology, Department of Pathology, Faculty of Medicine, Tottori University , Yonago, Japan
| | - Sayuri Hara
- 1 Division of Molecular Pathology, Department of Pathology, Faculty of Medicine, Tottori University , Yonago, Japan
| | - Michiko Matsushita
- 1 Division of Molecular Pathology, Department of Pathology, Faculty of Medicine, Tottori University , Yonago, Japan
| | - Satoshi Kuwamoto
- 1 Division of Molecular Pathology, Department of Pathology, Faculty of Medicine, Tottori University , Yonago, Japan
| | - Masako Kato
- 1 Division of Molecular Pathology, Department of Pathology, Faculty of Medicine, Tottori University , Yonago, Japan
| | - Ichiro Murakami
- 4 Department of Pathology, Kochi University Medical School Medical Course , Nankoku-shi, Japan
| | - Kazuhiko Hayashi
- 1 Division of Molecular Pathology, Department of Pathology, Faculty of Medicine, Tottori University , Yonago, Japan
| |
Collapse
|
49
|
Fukuta T, Nakamoto S, Hashimoto Y, Tanaka T, Tokuyasu Y, Maruyama J, Omura H, Hino N, Kuwamoto S, Murakami I. Acute undifferentiated leukemia (stem cell acute leukemia) showing differentiation to Langerhans cell-like cells in lymph nodes. Rinsho Ketsueki 2017; 58:26-31. [PMID: 28190861 DOI: 10.11406/rinketsu.58.26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
A 75-year-old woman was referred to our hospital with suspected leukemia. Complete blood count demonstrated WBC 3,810/µl with 26% blasts, Hb of 11.7 g/dl and Plt of 18.0×104/µl. Bone marrow aspiration revealed blasts (86.3%) with expressions of CD34, CD7, TdT, CD33, and CD117. MPO was negative. Chromosomal analysis of the bone marrow showed isolated trisomy 10 in all leukemic cells (20/20). Swelling of superficial lymph nodes was also observed. Cervical lymph node biopsy revealed leukemic blasts which had the same phenotype as those in the bone marrow except that proliferation of Langerhans cell-like cells (LCs) was observed in the paracortex. LCs had pale cytoplasm and grooved nuclei, and were positive for both CD1a and S100 protein. Trisomy 10 was detected in both the leukemic blasts and the LCs by fluorescence in situ hybridization. This rare case strongly suggests leukemic cells to differentiate into LCs.
Collapse
Affiliation(s)
- Takanori Fukuta
- Department of Pathology, Tottori Prefectural Central Hospital
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Kumata K, Nagata K, Matsushita M, Kuwamoto S, Kato M, Murakami I, Fukata S, Hayashi K. Thyrotropin Receptor Antibody (TRAb)-IgM Levels Are Markedly Higher Than TRAb-IgG Levels in Graves' Disease Patients and Controls, and TRAb-IgM Production Is Related to Epstein-Barr Virus Reactivation. Viral Immunol 2016; 29:459-463. [PMID: 27529807 PMCID: PMC7307640 DOI: 10.1089/vim.2016.0043] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
Graves' disease is an autoimmune thyroid disorder that mainly presents as hyperthyroidism and is caused by thyrotropin receptor antibodies (TRAbs) that stimulate thyroid-stimulating hormone receptors. We previously reported that Graves' disease patients and healthy controls both had Epstein–Barr virus (EBV)-infected TRAb-positive B cells and the EBV-reactivated induction of these B cells in cultures may induce the production of TRAbs. In the present study, we quantified serum TRAb-IgG and TRAb-IgM levels in 34 Graves' disease patients and 15 controls using ELISA to elucidate the mechanisms underlying EBV-related antibody production. As expected, TRAb-IgG and TRAb-IgM levels were higher in Graves' disease patients than in controls; however, TRAb-IgM levels were significantly higher than those of TRAb-IgG levels, whereas total IgM levels were lower than total IgG levels. On the other hand, the enhanced production of TRAb-IgM was frequently observed in patients with EBV reactivation. These results are consistent with the fact that the percentage of autoreactive IgM B cells are higher than that of autoreactive IgG B cells, and support the EBV-related polyclonal B cell activation. It is necessary to clarify the biological characteristics of TRAb-IgM and the relationship between TRAb isotypes and the biology of Graves' disease.
Collapse
Affiliation(s)
- Keisuke Kumata
- 1 Division of Molecular Pathology, Department of Pathology, Faculty of Medicine, Tottori University , Yonago, Japan
| | - Keiko Nagata
- 1 Division of Molecular Pathology, Department of Pathology, Faculty of Medicine, Tottori University , Yonago, Japan
| | - Michiko Matsushita
- 1 Division of Molecular Pathology, Department of Pathology, Faculty of Medicine, Tottori University , Yonago, Japan
| | - Satoshi Kuwamoto
- 1 Division of Molecular Pathology, Department of Pathology, Faculty of Medicine, Tottori University , Yonago, Japan
| | - Masako Kato
- 1 Division of Molecular Pathology, Department of Pathology, Faculty of Medicine, Tottori University , Yonago, Japan
| | - Ichiro Murakami
- 2 Department of Pathology, Kochi Medical School , Nankoku, Japan
| | - Shuji Fukata
- 3 Internal Medicine, Kuma Hospital , Kobe, Japan
| | - Kazuhiko Hayashi
- 1 Division of Molecular Pathology, Department of Pathology, Faculty of Medicine, Tottori University , Yonago, Japan
| |
Collapse
|